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Recent studies have shown that treatment of pulmonary tuberculosis with isoniazid
plus p-aminosalicylic acid (PAS) at home is, in the majority of cases, as satisfactory as
treatment with the same combination of drugs in sanatorium and does not appear to expose
the patient’s contacts to any special risk. Before mass domiciliary chemotherapy can be
introduced, however, a question that has to be decided is what drug or drugs and what
dosage and rhythm of administration will be most effective.
This paper presents the results of a controlled comparison of four chemotherapeutic
regimens :(a) 3.9-5.5 mglkg body-weight of isoniazid plus 0.2-0.3 g/kg body-weight
of PAS (sodium salt) daily in two doses (the standard combined chemotherapy) ;
(b) 7.8-9.6 mglkg body-weight of isoniazid alone daily in one dose ; (c) 7.8-9.6 mg/kg
body-weight of isoniazid alone daily in two doses ;(d) 3.9-5.5 mg/kg body-weight of
isoniazid alone daily in two doses.I oniazid plus PAS proved to be the most satisfactory
regimen; it was clinically effective and there were very few toxic manifestations.
I. INTRODUCTION
GENERAL
A controlled comparison of the merits of four
different chemotherapeutic regimens in the domici-
 liary treatment of pulmonary tuberculosis for a
  period of 12 months has been completed at the
Tuberculosis Chemotherapy Centre, Madras, and
the following is a report of the results. The patients
are being studied for a second and a third year,
some receiving further chemotherapy. These findings
will be reported later.
The formation of the Centre and its general
objects have been described in an earlier report
(Tuberculosis Chemotherapy Centre, 1959). The
principles were agreed upon in October 1955 at a
joint meeting in New Delhi of the Tuberculosis Sub-
Committee of the Indian Council of Medical
Research (ICMR) and representatives of the World
Health Organization (WHO) and the Medical
Research Council of Great Britain (MRC). It was
decided that there were a number of problems in
the chemotherapy of tuberculosis, relevant to the
launching of mass campaigns in under-developed
countries, which urgently required scientific investiga-
tion. The first and most important need was for an
investigation of the efficacy of treatment at home as
compared with treatment in sanatorium, including
a study of the risks to which treatment of patients
at home might expose their contacts. Secondly,
bec use chemotherapy with isoniazid alone was
being used on an increasing scale in India, it was
important to investigate closely the efficacy of
isoniazid when used alone, compared with standard
combined chemotherapy, as well as the epidemio-
logic  consequences of an increase in the number
of patients in the community excreting isoniazid-
resistant organisms. The study of isoniazid alone
has since become of even greater importance, for
a n mber of authorities have either recommended
the use of isoniazid alone in the conditions that
obtain in many parts of India (McDermott, 1956)
or have considered its use justifiable pending further
research of the type reported here (World Health
Organ zation Study Group on Chemotherapy and
Chemoprophylaxis in Tuberculosis Control, 1957).
Als , in 1957, UNICEF made substantial supplies
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of isoniazid available, through the Indian Govern-
ment, for use, alone, in a number of selected tuber-
culosis clinics. The considerable controversy con-
cerning the use of isoniazid alone has been reviewed
in a recent report (East African/British Medical
Research Council Isoniazid Investigation, 1960).
The 1955 meeting in New Delhi recommended
that a special research centre be established; the
Madras Government elected to co-operate in the
project and agreed to its being located in Madras
City. The Centre opened in May 1956 and began
its first major study, the comparison of home and
sanatorium treatment, in September 1956. Some of
the findings of this study, both for patients and their
contacts, have already been reported (Tuberculosis
Chemotherapy Centre, 1959; Andrews et al., 1960; l
Velu et al., 19602). The present report is concerned
with the second major issue, that is, the efficacy of
isoniazid alone, and gives the findings of a study of
the merits of three different regimens of isoniazid
alone compared with isoniazid plus p-aminosalicylic
acid (PAS). This standard form of oral combined
chemotherapy, when given for a year, has already
been shown to be effective in the domiciliary treat-
ment of patients in Madras City (Tuberculosis
Chemotherapy Centre, 1959).
The members of the senior scientific staff of the
Centre with major responsibility for the work re-
ported here are: Dr Wallace Fox (WHO), Senior
Medical Officer; Dr R. H. Andrews (WHO), Dr C.
V. Ramakrishnan (ICMR) and Dr S. Velu (Madras
Government), Medical Officers; Dr S. Devadatta
(ICMR), Assistant Medical Officer; Dr A. L.
Bhatia (ICMR) and Dr J. B. Selkon (WHO),
Bacteriologists; Dr P. R. J. Gangadharam (ICMR),
Assistant Bacteriologist; Mr T. V. Subbaiah
(ICMR), Laboratory Research Assistant; Mr S.
Radhakrishna (Madras Government), Statistician.
The research of the Centre is guided by a Project
Committee consisting of three ICMR representatives
(Dr P. V. Benjamin, Convenor, Dr J. Frimodt-
Møller and Dr K. S. Sanjivi), the Director of the
ICMR (Dr C. G. Pandit), the Director of Medical
Services, Madras State (Dr V. R. Thayumanaswamy),
a WHO representative (appointed for each meeting),
an MRC representative (appointed for each meeting)
and the Senior Medical Officer of the Centre (Dr
Wallace Fox).The joint secretaries are Mrs K.
Daniels and Mr B. S. Verma.
1 See article on page 463 of this issue.
2 See article on page 511 of this issue.
The MRC, through its Tuberculosis Research
Unit, is responsible for the scientific direction of the
research, in accordance with plans prepared by the
Project Committee. Dr Wallace Fox of the Tuber-
culosis Research Unit has been seconded to WHO
to serve as the Senior Medical Officer and the
Director of Research at the Centre. Close contact is
maintained between the Centre in Madras, the
MRC Tuberculosis Research Unit (Dr P. D’Arcy
Hart) and the MRC Group for Research on Drug
Sensitivity in Tuberculosis (Dr D. A. Mitchison and
Dr J. G. Wallace) in London. Dr Ian Sutherland of
the MRC Statistical Research Unit has advised on
statistical aspects.
The great majority of the patients in the present
study were referred to the Centre from the Govern-
m nt Tuberculosis Institute, Madras, the Director
of which during the period of intake was first
Dr P. R. Mudaliar and then Dr M. A. Hamid, and
the Corporation Tuberculosis Clinic, Pulianthope,
the Medical Officer in Charge of which was Dr K.
Narayana Murthi.The analysis was undertaken
and the report was prepared in the Tuberculosis
Chemotherapy Centre by the Centre’s medical and
statistical staff, Dr Wallace Fox and Mr S. Radha-
krishna being the co-ordinators.
GENERAL OBJECTS OF THE STUDY
The study reported here was designed to yield
information on the following aspects of the treatment
of pulmonary tuberculosis among patients living
in an adverse urban environment in South India. 
(1) The progress of patients treated in their homes 
with three alternative regimens of isoniazid alone
in comparison with the progress of patients treated
with standard combined chemotherapy.
(2) The extent to which the infectivity of patients
treated at home can be reduced by these different
regimens of chemotherapy.
(3) The prevalence of tuberculosis in close family
contacts at the time of diagnosis of the patient
ad itted to the study and the subsequent incidence
of uberculosis among them, with particular refe-
r nce to the drug sensitivity and the guinea-pig
virulence of the strains isolated from both the index
cases and their contacts.
(4) The identity and the virulence in the guinea-
pig of the strains isolated before treatment, and
the relation of the virulence to the response of the
patients to treatment.
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(5) Therel ta ionshipbetween the emergence of(6) The rate of inactivation of isoniazid and its
isoniazid resistance and the guinea-pig virulence,elation to isoniazid toxicity and the response of
the catalase activity and the hydrogen peroxidethe patients to treatment.
susceptibility of the resistant strains, and theirThe present report is concerned principally with
relation to the response of the patients to treat-the first and second of these points. The other
ment. subjects will be reported fully elsewhere.
II. GENERAL PLAN AND CONDUCT OF THE STUDY
SOURCE OF CASES
All the patients presented at local clinics with
symptoms. Mass miniature radiography was not
used as a source of cases. (For further details see
the 1959 report.) The great majority of patients
came from the poorest sections of the population of
Madras City.
AREA OF INTAKE
Madras City has a population of approximately
1 750 000. The area of intake for the present study
was approximately 20 square miles (50 km2) and
included 750 000 of this population.
DEFINITION OF ELIGIBLE CASES
With certain exceptions listed below, a patient
with pulmonary tuberculosis was eligible for the
study if all the following conditions were satisfied:
(1) The patient had either had no previous anti-
 tuberculosischemotherapy, orantituberculosis
chemotherapy had been administered for not more
than two weeks.
(2) The sputum was positive for tubercle bacilli
either on direct smear examination or on culture.
(3) The patient was aged 12 years or more.
(4) The patient was living in Madras City in the
defined area of intake (and was thus accessible for
home visiting) and was likely to remain there for
several years.
(5) The patient was prepared to :
(a) accept treatment at home for at least one year;
(b) accept treatment whether with tablets or injec-
tions;
(c) permit home visiting.
(6) The family was judged to be co-operative.
By adopting these criteria it was hoped to admit
both newly diagnosed cases and old cases which had
had no (or very little) previous chemotherapy, to be
able to treat them for at least 12 months, and to
follow them up for five years. In addition, it was
the intention to examine all the close family contacts
of each patient, by both radiography and tuberculin
testing, at regular intervals over the 5-year period.
(Findings on these contacts will be published separ-
ately.)
A patient was considered ineligible for the study
if any of the following applied at the time of assess-
ment :
(1) The patient was too ill to be treated at home
(e.g., was nearly moribund, had a spontaneous
pneumothorax or had had a severe haemoptysis).
(2) The patient had a pleural effusion obscuring
more than one-third of a lung field, as seen on a
postero-anterior chest radiograph.
(3) The patient had a non-respiratory form of
tuberculosis which it was considered would com-
plicate treatment.
(4) The patient was known to have leprosy.
(5) The patient was known to have a serious con-
comitant disease, such as diabetes.
(6) The patient was known to be pregnant.
PRETREATMENT INVESTIGATIONS
The following investigations were made before the
start of chemotherapy in the present study:
(1) Clinical examination and assessment of the
general clinical condition.
(2) A full-plate postero-anterior chest radiograph.
(3) Weight (lb.)
(4) Erythrocyte sedimentation rate (ESR Wester-
gren 200 mm, reading in mm at one hour).
(5) An intracutaneous tuberculin (Mantoux) test
with 5 tuberculin units (TU) of a purified protein
derivative (PPD, batch RT22) on the left arm. If the
greatest diameter of induration was less than 10 mm
at 48 hours (sometimes 72 hours), a 100 TU test was
undert ken on the right arm and this was also read
at 48 hours (sometimes 72 hours).
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(6) Examination of the urine for albumin and for
sugar.
(7) The examination by direct smear and culture
of a minimum of four sputum specimens, two
produced on demand and within a matter of
minutes in the Centre (“ spot ” specimens) and two
produced overnight in the home (“ collection ”
specimens).
(8) Tests of sensitivity to isoniazid, PAS and
streptomycin on two cultures, usually one from a
spot specimen and the other from a collection
specimen.
(Other bacteriological investigations are referred
to on page 542.)
In addition to the above, a detailed inquiry was
made into previous chemotherapy.
Before accepting a patient for treatment the co-
operation to be expected both from the patient and
from the family was assessed both in the Centre
and in the home by the health visitors, public health
nurses, social workers and doctors.
THE CHEMOTHERAPEUTIC REGIMENS
Four chemotherapeutic regimens were studied
(Table 1). These were a standard oral combination
–namely, isoniazid plus PAS (PH)–and three
regimens of isoniazid alone. One of these three
regimens (H) contained the same dosage of isoniazid,
in the same rhythm, as the combination isoniazid
plus PAS; the other two contained the largest dose
of isoniazid which it seemed likely could be given
by itself without an unduly high proportion of the
patients developing peripheral neuritis. The high
dosage of isoniazid was studied because of the
possibility that it would have greater efficacy than
the low dosage. It was administered in one regimen
(HI-2) as two doses a day and in the other (HI-1) as
a single daily dose (at the suggestion of Dr J. Holm),
to see whether the rhythm was important either in
acceptability for self-administration or in thera-
peutic effectiveness.It was decided not to use
pyridoxine as a preventative of peripheral neuritis
(Biehl & Vilter, 1954; Tchertkoff et al., 1956) because
this vitamin is expensive (it has subsequently been
shown that it may possibly interfere with the thera-
peutic effectiveness of isoniazid (McCune et al.,
1957)). The details of the chemotherapy and the
dosage for patients weighing 100 lb. (45.4 kg) were as
follows :
PH. Isoniazid 200 mg plus PAS (sodium salt) 10 g
daily to be taken as eight cachets, four in the morning
and four in the evening; each cachet was white and
contained 25 mg of isoniazid and 1.25 g of PAS
(sodium salt).
HI-1. Isoniazid 400 mg daily to be taken as eight
tablets in a single dose in the morning; each tablet
was blue, weighed 0.5 g and contained 50 mg of
is iazid.
HI-2. Isoniazid 400 mg daily to be taken as eight
tablets, four in the morning and four in the evening;
the same tablets were used as in the HI-1 regimen.
H. Isoniazid 200 mg daily to be taken as eight
tablets, four in the morning and four in the evening;
ach tablet was pink, weighed 0.5 g and contained
25 mg of isoniazid.
The daily dosage was related to the patient’s
weight (Table 1). The mean daily dosage of isoniazid
at the start of chemotherapy was 4.6 mg/kg for the
PH series, 8.7 mg/kg for the HI-1 series, 8.7 mg/kg
for the HI-2 series and 4.5 mg/kg for the H series.
The mean daily dosage of PAS at the start of chemo-
therapy for the PH series was 0.23 g/kg.
If, at a monthly examination, it was found that a
patient had gained weight and had moved into a
higher weight category, the dosage was increased
appropriately; however, if a patient lost weight and
moved into a lower weight category, the dosage was
not reduced.
PRESCRIBED DURATION OF CHEMOTHERAPY
All four chemotherapeutic regimens were pres-
cribed for a period of 12 months in the first instance.
ALLOCATION OF CHEMOTHERAPY
The allocation of chemotherapy was made from
a pre-arranged list, prepared by the MRC Statistical
Rese rch Unit, which was based on random samp-
ling numbers and which had been incorporated in a
seri s of numbered sealed envelopes before the start
of the study. The allocation was made by the Centre’s
tatistical staff from the next envelope in the series.
N ither the medical nor the statistical staff nor any-
body lse in the Centre had prior knowledge of the
chemotherapy which any individual patient would
receive. The patients were allocated to the treatment
series in approximately the following proportions :
5 PH to 4 HI-1 to 4 HI-2 to 5 H, The HI-1 and
HI-2 series were allocated smaller numbers because
it was thought likely that the responses in these two
series would be similar, and that the findings might
the efore be amalgamated.
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TABLE 1
DA I LY  DOSAGE  OF  DRUGS  IN  RELAT ION  TO  BODY -WE IGHT
5 3 9
Number of
tablets or
cachets to be
taken daily
Actual amount of
drug given daily
Daily dosage in relation to
body-weight
Body-weight
Regimen
l b .  morn- even-
i ng ing
3 3
3 3
3 3
3 4
3 4
4 4
4 4
  6 0 - 6 9
  7 0 - 7 9
20.4-27.1
27.2-31.7
3 1 . 8 - 3 6 . 2
3 6 . 3 - 4 0 . 7
4 0 . 8 - 4 5 . 3
4 5 . 4 - 4 9 . 8
4 9 . 9 - 5 4 . 3
150 7.50
150 7.50
150 7.50
175 8.75
175 8.75
2 0 0 10.00
2 0 0 10.00
4 5 - 5 9 20.4-27.1 2 0 0
6 0 - 6 9 2 7 . 2 - 3 1 . 7 2 5 0
7 0 - 7 9 3 1 . 8 - 3 6 . 2 3 0 0
8 0 - 8 9 3 6 . 3 - 4 0 . 7 350
9 0 - 9 9 4 0 . 8 - 4 5 . 3 3 5 0
1 0 0 - 1 0 9 4 5 . 4 - 4 9 . 8 4 0 0
1 1 0 - 1 1 9 4 9 . 9 - 5 4 . 3 4 5 0
20.4-27.1
2 7 . 2 - 3 1 . 7
3 1 . 8 - 3 6 . 2
3 6 . 3 - 4 0 . 7
4 0 . 8 - 4 5 . 3
4 5 . 4 - 4 9 . 8
4 9 . 9 - 5 4 . 3
2 0 0
2 5 0
3 0 0
350                     
3 5 0
4 0 0
4 5 0
I
   0 . 3 7 - 0 . 2 87.3-5.6                       5
9
2 6
2 8
15
6
1
5 . 5 - 4 . 8 0 . 2 7 - 0 . 2 4
4 . 7 - 4 . 2 0.23-0.21
4 . 8 - 4 . 4 0 . 2 4 - 0 . 2 2
4 . 3 - 3 . 9 0 . 2 1 - 0 . 1 9
4.4-4.1                        o-22-0.20
0 . 1 9
–
4 5 - 5 9
6 0 - 6 9
7 0 - 7 9
8 0 - 8 9
9 0 - 9 9
1 0 0 - 1 0 9
1 1 0 - 1 1 9
9 . 8 - 7 . 5
9 . 2 - 8 . 0
9 . 4 - 8 . 4
9 . 6 - 8 . 7
8 . 6 - 7 . 8
8.8-8.1
9 . 0 - 8 . 3
9 . 8 - 7 . 5
9 . 2 - 8 . 0
9 . 4 - 8 . 4
9 . 6 - 8 . 7
8 . 6 - 7 . 8
8.8-8.1
9 . 0 - 8 . 3
H i - l
9
7.3-5.6                                                             -
5 . 5 - 4 . 8 -
4 . 7 - 4 . 2 -
4 . 8 - 4 . 4 -
2
10
1 6
32
14
1 1
2
20.4-27.1 150 - 3 3
2 7 . 2 - 3 1 . 7 150 - 3 3
3 1 . 8 - 3 6 . 2 150 - 3 3
3 6 . 3 - 4 0 . 7 175 - 3 4
4 0 . 8 - 4 5 . 3 175 - 3 4
4 5 . 4 - 4 9 . 8 2 0 0 - 4 4
4 9 . 9 - 5 4 . 3 2 0 0 / - / 4 4
/ I I
4.3-3.9 -
4.4-4.1  -
4 . 0 - 3 . 7 -
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The first allocation was made on 5 October 1957
and the intake was stopped on 6 December 1958, by
which date 342 patients had been allocated to the
treatment series. One patient allocated to the HI-1
series left the district immediately and never com-
menced chemotherapy.Of the remaining 341
patients, 96 were allocated to the PH, 75 to the HI-1,
75 to the HI-2 and 95 to the H series.
It was originally intended to admit at least 360
patients to this study, but the intake was stopped as
soon as it became evident from a preliminary ana-
lysis that enough patients had been admitted to
permit the relative merits of the four chemothera-
peutic regimens to be determined.
GENERAL MANAGEMENT
The patients were treated in their own homes,
with supervision at the Centre of their progress.
The great majority attended the Centre weekly
throughout the 12 months for supplies of medicine.
Further, a visit was usually paid to the home each
week during the first month by a health visitor, and,
less regularly, by a doctor or a public health nurse.
Less frequent visits were made in later months,
though the number was not usually less than two
per month. The object of one of these visits was to
deliver a sputum specimen bottle and that of the
other, an unexpected visit, was to count the stock
of medicament and collect a specimen of urine for
testing, to check whether the patient was taking the
medicine.
Patients who were initially too ill to attend weekly
rested at home for the first month and were then
brought to the Centre by ambulance for examination
and re-assessment. As soon as they had improved
sufficiently, which was usually after one month of
treatment, they were changed to the ordinary
routine of clinic and home visits. The patients
were advised, if working, to stop work initially and
to rest, and the majority did so, although rest was
rarely strictly observed except by patients feeling
really ill.The majority of the patients were ambulant
much of the time and were quite often not at home
when visited, especially at surprise visits. Patients
were encouraged to return to work when they were
considered medically fit. A number of patients
returned to work before the Centre’s staff considered
them medically fit to do so.
ASSESSMENT OF PROGRESS
All the patients had examinations and assessments
at monthly intervals after the start of chemotherapy,
which included (a) a postero-anterior radiograph,
(b) examination of two sputum specimens by 
smear and culture, (c) in addition, from three
months onwards, a pair of laryngeal swabs for
culture, (d) tests of sensitivity to the allocated drug
or drugs on one positive culture, (e) measurement
of the weight (lb.), and (f) assessment of the degree
of ambulation and working capacity. The ESR was
determined every three months.
URINE TESTING FOR ISONIAZID OR PAS
In order to check the self-administration of the
medicine, a urine specimen was obtained at every
visit to the Centre and also at surprise visits to the
home, which the health visitor usually made once
a month. A napthoquinone-mercuric chloride test
for isoniazid (Short & Case, 1957; Gangadharam
et al., 1958) was performed on the specimens from
patients in the HI-1, HI-2 and H series. For patients
in the PH series, a ferric chloride test for PAS
(Simpson, 1956) was performed.
POWDERED MILK
Powdered milk was issued once a month to the
families of all the patients; the quantities, which were
the same as those supplied in the earlier study (Tuber-
culosis Chemotherapy Centre, 1959), were small.
III. BACTERIOLOGICAL PROCEDURES
BACTERIAL CONTENT OF SPUTUM SPECIMENS AND from each patient.At the end of three months,
LARYNGEAL SWABS and monthly thereafter, a pair of laryngeal swabs
was also obtained, In all, therefore, a patient was
Before the start of treatment a minimum of fourscheduled to have 38 specimens examined by the
sputum specimens was obtained–namely, two over-end of 12 months. All the sputum specimens were
night (collection) specimens and two clinic (spot)examined by smear and culture and the laryngeal
specimens. At the end of every month of treatmentswabs by culture only. The reasons for this pattern
two collection specimens of sputum were obtainedof bacteriological investigation and the details of
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the method of examination of the smears and the
proceduresfor culture of sputum and laryngeal
swabs have been described in the earlier report
(Tuberculosis Chemotherapy Centre, 1959). In
brief,smears were examined by fluorescence micro-
scopy and were graded as 3-plus, 2-plus, 1-plus and
negative.It was estimated that a 3-plus smear
contained more than 5000 bacilli per mm2, that
is, about 100 bacilli per field examined with a
totalmagnification of x 700. A 1-plus smear was
recorded when there were fewer than about 300
bacilli per mm2, that is, 6 bacilli per field under the
same magnification; a 2-plus smear, therefore, con-
tained between approximately 5000 and 300 bacilli
per mm2. Cultures were set up on Löwenstein-
Jensen medium without potato starch (Jensen, 1955),
and were examined weekly for between eight and
nine weeks; they were reported as negative if no
growth was present by that time. Positive cultures
were graded when they first showed growth as
3-plus if the growth was confluent, as 2-plus if there
were innumerable discrete colonies and as 1-plus
if there were 100-20 colonies; the number of colonies
was recorded if this was less than 20.
SENSITIVITY TESTS
Tests of sensitivity to isoniazid, PAS and strepto-
mycin were performed on two cultures obtained
before the start of treatment, one from a spot and
one from a collection specimen. After the start of
treatment tests of sensitivity to the allocated drug or
drugs were performed on one positive culture at
every month in which positive cultures were obtained.
sensitivity tests were set up on Löwenstein-Jensen
 medium slopes containing the concentrations of drug
set out below, as well as on a drug-free slope as a
control. The standard sensitive strain, H37Rv, was
also set up with each batch of tests. The details of
the procedures
(op. cit.)
have beengivenin theearlierreport
The drug concentrations used were as follows:
lsoniazid :
Drug concentrations
in µg/ml
Test strain
H37Rv
Sodium PAS dihydrate :
Test strain
H37Rv
0.2, 1, 5, 50
0.025, 0.05, 0.1, 0.2,1
2, 4, 8, 16, 64
0.25, 0.5, 1, 2, 4
Streptomycin:
Test strain 4, 8, 16, 32,1024
H37Rv 1, 2, 4, 8
DEFINITIONS OF BACTERIAL DRUG RESISTANCE
In the following definitions of drug resistance,
“ growth ” has been defined as 20 or more colonies.
Isoniazid
Pretreatment tests. Resistance was defined as:
(a) growth on 1 µg/ml or a higher concentration,
even if the result of a test on a second culture was
sensitive ;
(b) growth on 0.2 µg/ml, followed by the same
result on a repeat test on the same culture, even if
the result of a test on a second culture was sensitive;
or
(c) growth on 0.2 µg/ml for two separate cultures
(irrespective of the results of repeat tests).
Tests during treatment. Resistance was defined as:
growth on 0.2 µg/ml or a higher concentration.
This definition differs slightly from that used in the
earlier report (Tuberculosis Chemotherapy Centre,
1959) in that growth on 0.2 µg/ml has now been
classified as indicating resistance, irrespective of
the results of any repeat tests. This modification
has been introduced in the present study because in
a series of 89 such repeat tests in the present study,
only 12 failed to show growth on 0.2 µg/ml or a
higher concentration.Moreover, in 10 of these 12
instances, resistant results were obtained at the
ucceeding month or at both the preceding and the
succeeding months.
S reptomycin
Pretreatment tests. Resistance was defined as:
(a) a resistance ratio of 8 or more, or a resistance
ratio of 4 followed by a ratio of 4 or more on a
repeat test on the same culture, even if the result
of a test on a second culture was sensitive; or
(b) a resistance ratio of 4 for each of two separate
cultures.
The resistance ratio was defined as the minimal
drug concentration inhibiting growth of the test
strain divided by the minimal drug concentration
inhibiting growth of strain H37Rv.
PAS
The definitions of PAS resistance used in the
1959 report are not appropriate to the present
study. The findings for the present study are con-
sidered in section VIII.
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OTHER INVESTIGATIONS
A number of other tests were undertaken on
strains isolated from specimens obtained before the
start of chemotherapy :
(1) Estimation of the catalase activity of all
strains from each patient by a qualitative method.
(2) Estimation of the catalase activity of a sample
of strains by a semi-quantitative method (Kreis,
Le Joubioux & Pariente, 1956).
(3) A series of identification tests on one strain
from each patient.
(4) Estimation of the virulence in the guinea-pig
of one strain from each patient.
(5) Estimation of the susceptibility to hydrogen
peroxide of a small sample of strains.
During chemotherapy the following estimations
were made monthly :
(1) The qualitative catalase activity of all the
strains on which sensitivity tests were performed.
(2) The semi-quantitative catalase activity of all
the isoniazid-resistant strains.
The following tests were made on one strain
fro  each patient at six, nine and 12 months after
the start of chemotherapy:
(1) A series of identification tests.
(2) A guinea-pig virulence test.
(3) A hydrogen peroxide susceptibility test.
The results of these other bacteriological investiga-
tions will be fully reported elsewhere. The pre-
t eatment virulence findings are summarized in
section VI.
IV. THE PATIENTS ADMITTED TO TREATMENT
CLASSIFICATION
In all, 341 patients were admitted to treatment,
96 to the PH, 75 to the HI-1, 75 to the HI-2 and 95
to the H series. Of these, 22 (6 PH, 3 HI-1, 7 HT-2,
6 H) were subsequently found to have been excreting
isoniazid-resistant organisms before treatment. These
patients have been separated from the main analysis
and are considered in section XII. Only four
other patients were removed from the main analysis.
Of these, one patient (H) who had organisms
sensitive to isoniazid had received more than
two weeks of previous chemotherapy (probably
including isoniazid). Another patient (H) died from
a carcinoma of the bronchus which had complicated
the interpretation of the course of the tuberculosis.
One patient in the HI-1 series took his own discharge
from treatment in the second month, and another
HI-1 patient was advised, in error, by a member of
the staff to take his medication in two doses a day
instead of one and did so for two months. There
remain 315 patients (90 PH, 70 HI-1, 68 HI-2,
87 H) who contribute to the main analysis. These
patients conformed to the following especially
important criteria :
(a) of having, on admission to the study, organ-
isms sensitive to isoniazid;
(b) of having had, as far as is known, no previous
chemotherapy or, in 2 PH, 3 HI-1, 4 HI-2 and 2 H
patients, up to two weeks’ chemotherapy; and
(c) of having followed the prescribed regimen for
12 months with, at most, minor variations, unless
chemotherapy was stopped or changed owing to
death, tuberculous deterioration or major toxicity.
Six patients (1 PH, 1 HI-1, 2 HI-2, 2 H) who had
streptomycin-resistant strains before treatment have
been left in the main analysis since none of the
regimens included streptomycin.
No attempt has been made to exclude from the
analy is any patients who may have had PAS-
resistant strains before the start of treatment 
because of the difficulty in the present study 
identifying such patients with certainty (see section
VIII). The test results suggest (see page 567) that
between four and eight of the 315 patients in the
main analysis (and not more than four in the PH
series) had primary PAS-resistant strains. Their
inclusion in the analysis may have put the PH
series at a minor disadvantage.
PRETREATMENT COMPARISON BETWEEN THE FOUR
SERIES
Age, sex and religion
The age and sex distributions are given in Table 2.
Of the 90 patients in the PH series 63 % were males,
compared with 54% of 70 in the HI-1 series, 72% of
68 in the HI-2 series and 63 % of 87 in the H series.
The distributions of estimated age were reasonably
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similar for the four series. Most of the patients
–namely, 78 % of the PH, 93 % of the HI-1, 87 % of
the HI-2 and 80% of the H series–were between the
ages of 15 and 44 years. The differences between the
series are unimportant since age is not associated
with the prognos is (page 564).The religion of the
patients is also shown in Table 2; 89% of the PH,
79 % of the HI-1, 85 % of the HI-2 and 89 % of the
H patients were Hindus, and the rest were either
Moslems or Christians.
Clinical, radiographic and bacteriological condition
Table 3 shows the condition of the patients at the
time of admission to treatment, as indicated by the
general condition, the weight, the ESR, the extent
of cavitation, the total extent of the radiographic
lesion and the number of lung zones involved in
disease.
The extent of cavitation, the total extent of the
radiographic lesion and the number of lung zones
involved in disease were reported from a single full-
plate radiograph by an independent assessor (Dr Raj
Narain), who was unaware of the treatment series of
any patient. The assessor graded the extent of
cavitation on each film as extensive, moderate,
slight or nil, and then checked the consistency of the
grading by reviewing the films in batches, grade by
grade (Fox & Sutherland, 1956). He assessed the total
extent of the radiographic lesion in six grades
according to the following classification : (1) trivial,
that is, minimal lesions which the assessor regarded,
purely on radiographic grounds, as inactive; (2)
slight, that is, minimal or rather larger lesions which
he regarded as radiographically active; (3) limited,
that is, lesions of greater extent than in (2) but
involving a total area of lung less than that occupied
by the right upper lobe as visualized on a postero-
anterior radiograph; (4) moderate, that is, lesions of
greater extent than in (3) but whose total extent,
even if bilateral, did not exceed an area equivalent
to the whole of one lung; (5) extensive, that is,
lesions which involved an area of more than the
whole of one lung;and (6) gross, that is, very
extensive bilateral disease. Having graded each
radiograph, the assessor checked the consistency of
the grading by reviewing the films in batches, grade
by grade. He assessed the number of lung zones
involved in disease using standard definitions of
zones (Daniels et al.,1948), and recording the
presence of any disease, no matter how limited in
extent, in each zone.
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It will be seen from Table 3 that the four series of
patients had very similar distributions in respect of
the general condition,the weight and the ESR.
Considering the radiographic features, the PH series
was at a disadvantage, for 19% had extensive
cavitation compared with 10 % in the HI-1, 7 % in the
HI-2 and 9 % in the H series. Also, 17 % of the PH
series had gross disease compared with 7 %, 3 % and
9 % for the other three series, respectively, and 21%
of the PH series had six lung zones involved com-
pared with 13 %, 13 % and 10 %, respectively.
Considering extensive cavitation and gross disease
(not tabulated here), 24 (27%) of the PH, nine  
(13 %) of the HI-1, five (7 %) of the HI-2 and 14   
(16 %) of the H series had one or both of these
undesirable features. The occurrence of such large
pretreatment differences between four series, with
random allocation, is most unusual (P < 0.01).
Table 4 presents the condition of the patients
on admission to treatment as reflected by the
bacterial content of four sputum specimens (two
collection and two spot specimens). (Owing either
to failure to collect all the required specimens or to
contamination of cultures, complete results were not
available for a small proportion of the patients.
However, all the patients had at least one spot
specimen and allexcept three (2 PH, 1 H) had at least
one collection specimen.) Considering the findings
on the first (or only) collection specimen, 74% of
88 PH patients, 91% of 70 HI-1, 88 % of 68 HI-2 and
85% of 86 H patients had a positive smear. The
corresponding proportions were 78%, 83 %, 83 %
and 84 % for the second collection specimen, 68%  
74%, 76 % and 79 % for the first spot specimen and  
70%, 77 %, 73 % and 78 % for the second spot  
specimen.The differences are greatest for the first
collection specimen.Although the patients in the
PH series had a smaller bacterial content of sputum
on admission to treatment than those in the other
three series, the differences between the four series
are unusually large (P<0.02) only for the first
collection specimen.
To summarize, the PH series was at a disadvantage
radiographically and at an advantage bacteriologi-
cally. The pretreatment condition of the PH series
has therefore been regarded, on balance, as similar
to that of the other three series.
(A special analysis–not tabulated here–was made
to study the effect upon the results of these pre-
treatment differences between the PH and the other
three series. Measures of radiographic and bacterio-
logical response to treatment in each of the four
TABLE 3
CLINICAL AND RADIOGRAPHIC CONDITION ON
ADMISSION TO TREATMENT
HI-2 1 H
No. %  No. %
PH HI-1
No. % No. %
General condition :
Good 16 1 8 15 2 1 15 2 2 15 1 7
Fair 53 5 9 44 6 3 37 5 4 53 6 1
Poor 18 2 0 11 1 6 15 2 2 19 2 2
Very poor 3 3 0 0 1 1 0 0
Weight (lb.“) :
Under 60
60-69
70-79
so-39
90-99
100-109
110 or more
5 6 0 0 1 1 2 2
9 1 0 12 1 7 10 1 5 10 1 1
26 2 9 16 2 3 10 1 5 16 1 8
28 3 1 20 2 9 20 2 9 32 3 7
15 1 7 14 2 0 17 2 5 14 1 6
6 7 5 7 9 1 3 11 1 3
1 1 3 4 1 1 2 2
ESR (mm in 1 hour):
0 - 1 0 0 0 1 1
1 1 - 2 0 3 3 2 3
2 1 - 5 0 24 2 7 16 2 3
5 1 - 1 0 0 44 4 9 40 5 7
101 or more 19 2 1 11 1 6
1 7 1 7
4 6 2 2
14 2 1 20 2 3
36 5 3 52 6 0
13 1 9 12 1 4
Extent of cavitation :
Nil
Slight
Moderate
Extensive
8 9 1 1 5 7 8 9
24 2 7 2 6 37 19 2 8 25 2 9
41 4 6 36 51 39 5 7 46 5 3
17 1 9 7 10 5 7 8 9
Total extent of disease :
Trivial 5 6 1 1 2 3 4 5
Slight 3 3 3 4 3 4 5 6
Limited 16 1 8 20 2 9 19 2 8 17 2 0
Moderate 33 3 7 29 4 1 28 4 1 34 3 9
Extensive 18 2 0 12 1 7 14 2 1 19 2 2
Gross 15 1 7 5 7 2 3 8 9
Number of lung zones  
involved in disease :
14 1 6 13 1 9
19 2 1 23 3 3
22 2 4 12 1 7
19 2 1 9 1 3
2 3 4 5
13 1 9 13 1 5
13 1 9 15 1 7
15 2 2 14 1 6
16 2 4 32 3 7
9 1 3 9       10 
Total patients 90 100  70 1 0 0 6 8  100 8 7  100
* 1 lb.=0.45 kg.
TABLE 4
BACTERIAL CONTENT OF SPUTUM ON ADMISSION TO TREATMENT
Second collection specimen First (or only) spot
specimen
First (or only) collection
specimen Second spot specimen
Bacterial content of sputum
     PH  HI-1  HI-2 H
No. %
6 7 0 0 2 3 2 2
5 6 2 3 3 4 5 6
12 14 4 6 3 4 6 7
14 16 19 27
_ _ _ _ _ _
24 27 17 24 22 3 2 30 3 5
27 31 28 40 25 37 32 3 7
H
No. %
5 6 I 2 1 2
6 7 2 3 2 3 6 9 4 6 5 6
 
7 9 7 12 8 1 2
4 5 3 3
7 9 17 1 9 9 13 9 1 3 9 1 0
    
Culture
negative
Culture less
than 20 coloniesDirect smearnegative
Culture 20
colonies or
more
Smear l-plus
(scanty)
Direct smear Smear 2-plus
positive * (moderate)
1 0 11 4 6 3 5
8 9
26 30
8 12 11 17 ] 12 14
24 37 21 32 25 30
7 26 28 34
10 1 2
22 3 2 23 2 6 1
 
5 7
68 99 87 9 9
28 35 16 27 24 3 6
25 31 23 38 22 3 3 12 14
83 99Total patients tested
* Even if the culture was negative.
I
8 100 65 100
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treatment series during the 12 months were standard-
ized statistically for pretreatment differences both
in the extent of cavitation and in the bacterial
content of the sputum. The results were practically
unaltered by the standardization. In other words,
the net effect on the results of the radiographic
disadvantage and the bacteriological advantage
before treatment in the PH series was negligible.)
CO-OPERATION OF THE PATIENTS
The co-operation obtained from the 341 patients
admitted to treatment in the present study was
excellent, only one patient absconding during the
year. He and all the other survivors were examined
at 12 months, so that information on the entire
group of 341 patients was available at the end of the
period.
PLAN OF THE REST OF THE REPORT
The next section (section V) describes the progress
of the 315 patients in the main analysis. Section VI
reports the study of virulence in the guinea-pig of
the strains isolated before treatment and its bearing
on the results of treatment. Section VII evaluates
the prognostic importance of various characteristics
at the start of treatment. Certain additional bacteri-
ological findings are presented in section VIII.
Analyses of toxicity and other clinical complications
of treatment are given in section IX. Sections X
and XI deal, respectively, with the self-administra-
tion of the medicine, and with rest and activity of
the patients and the financial status of their families.
The fin ings for the 26 patients not included in the
main analysis are considered in section XII. This
presentation of the results is followed by a discussion
(section XIII) and a summary (section XIV).
V. COMPARISON OF THE FOUR TREATMENT SERIES
Deaths
CLINICAL
There were 11 deaths among the 315 patients
during the 12-month period-namely, three (3 %)
of the 90 PH patients, one (1%) of 70 HI-1, two
(3 %) of 68 HI-2 and five (6 %) of 87 H patients.
Of the three PH patients, one (a female, aged 20)
died of smallpox in the fifth month of treatment.
The second (a female, aged 30) died in the seventh
month of treatment. There had been considerable
resolution of the lesion radiographically and all the
14 cultures examined from the first month of treat-
ment onwards were negative for tubercle bacilli.
She was admitted to hospital for investigation of
diarrhoea associated with oedema of the face and
legs, but passed into coma and died. The lumbar
puncture findings were normal. Permission for a
post-mortem examination was not obtained and
the cause of death was not established, but, in view
of the satisfactory response to treatment, it seems
unlikely to have been connected with the tuber-
culosis. The third patient (a male, aged 30) died in
the third month of treatment. Although he was
responding radiographically and bacteriologically
(the two culture results at two months being negative
and two colonies, respectively, compared with 3-plus
and 2-plus positive findings before treatment), the
patient developed symptoms of a secondary respira-
tory infection with a pleurisy and was admitted to
sanatorium; he died the same day. It is possible that
his pulmonary tuberculosis, although responding,
was at least a contributory cause of death.
The HI-1 patient (a female, aged 23) died in the
third month. She had evidence of both a radio-
raphic and a bacteriological response, but had had
a chronic diarrhoea for a number of months. This
led to generalized oedema. She died in hospital, 
and the cause of death was considered by the hospital
physician to be idiopathic tropical steatorrhoea,
permission for a post-mortem examination was not
obta ned.
One HI-2 patient (a male, aged 65), who was
respo ing both radiographically and bacteriologi-
cally to treatment, died in his sleep in the second
m nth. A cardiovascular catastrophe was considered
to be the most likely cause of death. The other
HI-2 patient (a male, aged 54) died of pulmonary
tub rculosis in the fourth month of treatment.
Of the five H patients, one (a female, aged 20),
with extensive disease and cavitation, died of
pulmonary tuberculosis in the third week of treat-
ment, and another (a male, aged 45), with gross
dise se and moderate cavitation, died in the fourth
week. The third (a male, aged 38) died in the second
mont  of treatment. At the start of treatment he
had a moderately extensive lesion with moderate
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cavitation which, at one month, showed a definite
improvement both radiographically and bacterio-
logically. However, he had had diarrhoea at intervals
for the previous nine months, associated with
anaemia.He developed oedema of the feet, and
was admitted to hospital for further investigation
and treatment after five weeks of chemotherapy, but
died suddenly. It was considered unlikely that the
tuberculosis contributed to his death. The fourth
patient (a female, aged 21) died early in the fourth
month of treatment. She showed no bacteriological
response, and the radiograph just before the end of
the third month of treatment showed a radiographic
    spread, confirmed by an independent assessor (see
next subsection), and it was decided to admit her to
sanatorium and change her chemotherapy. Within
two days she had developed a spontaneous pneumo-
thorax and, despite intercostal drainage and daily
streptomycin plus pyrazinamide, she died a week
later. The fifth patient (a female, aged 55) died in
the eighth month of treatment. She had failed to
respond to her therapy and at the end of four months
the independent assessor considered that there was
a radiographic spread and recommended a change
of chemotherapy; daily streptomycin plus pyrazina-
mide was commenced.The patient subsequently
developed a gastro-enteritis which led to a vitamin B
deficiency state,with oedema, ascites, anaemia,
glossitis and angular stomatitis.She received
vitamin B complex injections and packed cell
transfusions but failed to improve and died early in
the eighth month of treatment, there having been
light
  the sputum was still heavily positive. The primary
resolution of the radiographic spread, although
cause of death was pellagra, but the tuberculosis
    may have been a contributory factor. (This patient
has been classified in the rest of the report as having
had her chemotherapy changed owing to a deterio-
ration, and not as a tuberculous death.)
In the absence of post-mortem examinations it is
difficult to be certain of the precise cause of death
in several of these patients. Considering all the
evidence, it seems probable that one PH, one HI-2
and four H patients either died of pulmonary
tuberculosis or that the tuberculosis was a factor
contributing to death. With the exception of the
H patient who died more than three months after
a change of chemotherapy (see above), these patients
have been regarded as tuberculous deaths through-
out the rest of the report. It should be noted that
two of the deaths (in H patients) occurred in the
first month of therapy.
Cha g  of chemotherapy due to radiographic or
clinical deterioration
Radiographic spread of the disease is not un-
common in the first month of treatment, even in pa-
tients whose subsequent progress is very satisfactory.
For this reason a radiographic spread in the first
month was not regarded as an indication to change
the chemotherapy. In the course of a series of radio-
graphic assessments, an independent assessor (Dr
Raj Narain) was shown the radiographs on admission
and at one month for each patient and he repor-
ted on definite spreads of disease, no matter how local-
ized, and even if the over-all picture was one of im-
provement. Such spreads, many of which were minor,
occurred in 26% of the 90 PH patients, 27% of the
70 HI-1, 28 % of the 68 HI-2 and 21% of the 85 H
patients (two H patients had died in the first month).
If, during the course of the study, a patient was
considered by the Centre’s medical staff to have a
definite radiographic extension of the disease which
was not present at the first month, the following
procedure was adopted. The supervision of the
patient was intensified, a 7- to 10-day course of
penicillin was given and a further radiograph was
taken at the end of two weeks or at the next monthly
examination.A careful supervision for possible
radiographic evolution of the lesion was maintained.
If the new lesion was persisting or spreading, and
was more than minor, the complete radiographic
series was shown to an independent assessor,
Dr K. S. Sanjivi, who was unaware of the treatment
the patient was receiving. (This procedure was
adopted because of the observation of Oestreicher
et al. (1955) that the radiographic spreads which
occur under treatment with isoniazid alone fre-
quently resolve without change of chemotherapy.)
All the patients had a positive sputum when re-
viewed by the assessor. The assessor sometimes
decided that the disease had deteriorated radio-
graphically to such an extent that chemotherapy
should be changed; sometimes he considered that,
lthough a deterioration had occurred, it did not
warrant a change of chemotherapy. In the latter
circumstances he indicated when he wished to see
the radiographic series again. It will be appreciated
that a number of patients who changed chemo-
therapy because of a localized radiographic deterio-
ration still showed, at that time, general radiographic
improvement since the start of treatment.
Serious clinical deterioration was also regarded
as a ground for changing the chemotherapy, without
recourse to an assessor.
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During the course of the 12 months 35 patients
(1 (1%) PH, 5 (7%) HI-1, 14 (21%) HI-2 and 15
(17 %) H) had their treatment changed because of
definite deterioration (Table 5). The differences
between the PM series and the HI-2 and H series
each attain significance at the 0.1% level, and the
difference between the HI-1 and HI-2 series at the
5% level. In the majority of these patients (83 %)
the treatment was changed in the second six months.
Radiographic deterioration was confirmed by the
independent assessor in 33 patients. The remaining
two patients (both HI-2) had their chemotherapy
changed because of serious clinical deterioration in
one and an haemoptysis in the other.
One patient (HI-2) requires particular mention.
His chemotherapy was changed in the twelfth
month; he had peripheral neuritis as well as a radio-
graphic deterioration.Except in the section on
toxicity (section IX), this patient has been classified
T A B L E  5
D I S T R I B U T I O N  O F  C H A N G E S  O F  C H E M O T H E R A P Y  D U E
T O  D E T E R I O R A T I O N  A C C O R D I N G  T O  T H E  N U M B E R  O F
M O N T H S  O F  C H E M O T H E R A P Y  C O M P L E T E D
N u m b e r
o f  m o n t h s  o f
c h e m o t h e r a p y
c o m p l e t e d P H
1 0
2 0
3 0
4 0
5 0
6 1
7 0
8 0
9 0
10 0
1 1 0
T r e a t m e n t  s e r i e s Other departures from prescribed chemotherapy
H I - 1
0
0
0
1
0
0
0
1
0
2
1
0  0
0 0
   
*  O n e  m o r e  p a t i e n t ,  w h o  d e t e r i o r a t e d  r a d i o g r a p h i c a l l y  a f t e r
c o m p l e t i n g  t w o  m o n t h s  o f  t r e a t m e n t ,  t h e n  h a d  a  s p o n t a n e o u s
p n e u m o t h o r a x ,  a n d  d i e d  w i t h i n  a  w e e k  o f  a  c h a n g e  o f  c h e m o -
t h e r a p y .  S h e  h a s  b e e n  c l a s s i f i e d  a s  a  t u b e r c u l o u s  d e a t h
t h r o u g h o u t  t h i s  r e p o r t  ( s e e  p a g e  5 4 7 ) .
* *  T h e  p e r c e n t a g e s  a r e  b a s e d  o n  t h e  t o t a l  n u m b e r  o f  p a t i e n t s
i n  e a c h  t r e a t m e n t  s e r i e s  i n  t h e  m a i n  a n a l y s i s .
throughout the report as having the chemotherapy
changed owing to deterioration.
Changes of chemotherapy due to toxicity
In seven patients (1 PH, 5 HI-1 and 1 HI-2)
the treatment was changed on account of toxic
reactions to the chemotherapy. There was no
toxicity in the H series.The PH patient had her
chemotherapy changed in the third month following
a hypersensitivity reaction to PAS. The HI-1 patients
had their chemotherapy changed in the fifth, sixth,
seventh, tenth and eleventh months, respectively, and
the HI-2 patients in the sixth month, all on account
of peripheral neuritis.
It was decided that patients who departed for
more than six weeks from the prescribed chemo-
therapy on account of toxicity would be classified as
having the chemotherapy changed on account of
toxicity. This rule applied to one PH patient (in
addition to the one referred to above) who departed
from the prescribed chemotherapy for more than
three months during desensitization to PAS (see
page 569).
Some patients with toxic reactions did not have
their chemotherapy changed. All the toxic manifesta-
tions are described in section IX.
Two PH patients had their chemotherapy modified
to include streptomycin, for totals of 38 days and
17 days, respectively, the first during an attack of
jaundice, the second during desensitization to PAS
(see page 549). One patient received streptomycin
in place of PAS with the isoniazid during hospital  
investigations, and five more PH patients had no
supplies of chemotherapy for 41, 18, 17, 14 an
seven days, respectively. Five HI-1 patients had no
supplies of chemotherapy for 27, 23, nine, eight and
seven days, respectively, four HI-2 patients for 10,
eight, seven and seven days, respectively, and
eight H patients for 28, 14, 12, 11, 10, seven, seven
and seven days, respectively. These interruptions
of chemotherapy were usually due to the patient’s
absence from Madras without a supply of medicine
or admission to hospital for treatment of a non-
tuberculous condition.
Presentation of the results for the patients whose
chemotherapy was changed or who died
For the patients whose chemotherapy was changed
there was a problem concerning the best way to
present information about them after the changes
had occurred. Because the clinical findings subsequent
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to a change were not directly related to the chemo-
therapeutic regimen originally allocated, it was
decided to exclude these subsequent findings from
the tabulations.However, deterioration of the
tuberculous disease under treatment was often a
reason for the change of chemotherapy; if the fact
that a patient had had chemotherapy changed
owing to deterioration was not incorporated in the
tabulations for the subsequent months, a fair evalua-
tion of the progress of each treatment series could
not be made. To meet this difficulty, the changes
in chemotherapy were considered in two categories:
those due to deterioration and those due to toxicity.
    The changes due to deterioration represented direct
failures of the allocated chemotherapy to control
the tuberculous disease; these have been included,
under the heading of changes due to deterioration,
in each tabulation of the clinical results subsequent
to the month of change of treatment. The changes
due to toxicity, on the other hand, were not neces-
sarily associated with an unfavourable response of
the tuberculous disease; these have therefore been
excluded from all the tabulations after their
occurrence.
The patients who died presented a similar problem,
which was resolved in the same way. Those who
died of tuberculosis, or in whom tuberculosis con-
tributed to the death, have been included in the sub-
sequent tabulations as tuberculous deaths.The
patients who died of diseases other than tuberculosis
do not appear in the tabulations after their death.
Weight changes
   The weight changes for the 12-month period are
set out in Table 6. During the first six months
  nearly all the patients gained weight–namely, 94%
         of 83 PH, 97% of 64 HI-1, 90%  of 63 HI-2 and 77 %
of 82 H patients, In the second six months a number
of patients lost weight–namely, 46% of 80 PH,
41% of 58 HI-1, 36% of 61 HI-2 and 41% of 74 H
patients. Over the full 12-month period 90% of
82 PH, 90 % of 60 HI-1, 69 % of 64 HI-2 and 69 %
of 81 H patients gained weight.
Erythrocyte sedimentation rate
The distribution of the ESRs at the start of treat-
ment, at six months and at 12 months are set out
in Table 7. All four series showed a progressive
increase in the number of patients with a low ESR.
Thus, whereas three of 87 PH patients, three of
67 HI-1, five of 66 HI-2 and three of 86 H patients
had an ESR of 20 mm or less before treatment, at
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six months the numbers had increased to 29 for the
PH series, 26 for the HI-1, 25 for the HI-2 and 29
for the H series. At 12 months the numbers had
increased further in all four series, being 39 for the
PH, 33 for the HI-1, 31 for the HI-2 and 36 for the
H series. Although the ESR fell in many patients,
a considerable proportion in all four series retained
high ESRs, even at 12 months. The ESR is, however,
not a very satisfactory measure of activity of the
disease in Indian patients and high rates are quite
compatible with quiescent disease (Tuberculosis
Chemotherapy Centre, 1959; Velu et al., 1960 1).
Radiographic changes
The changes in the radiographic appearances
were assessed for the first six months, for the second
six months and for the whole period by an indepen-
dent assessor, Dr Raj Narain, who was unaware of
the treatment series to which any patient had been
allocated. He made three completely separate assess-
ments. First he was shown the pretreatment and
six-month radiographs, the patients being considered
in a random order, and he made an assessment of the
changes for the first six months. When this assessment
was complete for all the patients, a similar assess-
ment was made for the 12-month period, the assessor
being shown the pretreatment and the 12-month
radiographs of each patient. Finally, the radiographs
at six and 12 months were viewed and the changes
in the second six months were assessed. Four
grades were used for the classification of improve-
ment–namely, exceptional, considerable, moderate
and slight-and three for deterioration–namely 
slight, moderate and considerable.
The findings are set out in Table 8. Considering
the changes over the first six months, 79% of 87
PH, 73 % of 67 HI-1, 62% of 66 HI-2 and 69 % of
86 H patients showed moderate or greater improve-
ment. The proportions of patients who showed
radiographic deterioration but continued on the
initially allocated chemotherapy, who deteriorated
and had their chemotherapy changed during the
period, or who died of tuberculosis, were 2% of the
PH, 7% of the HI-1, 8 % of the HI-2 and 15 % of
the H series.
Over the full 12 months, the majority of the
patients showed moderate or greater improvement–
namely, 85 % of the PH, 78 % of the HI-1, 71% of
the HI-2 and 62% of the H series. The proportions
of patients who showed radiographic deterioration,
1 See article on page 511 of this issue.
T A B L E  8
C H A N G E S  I N  R A D I O G R A P H I C  A P P E A R A N C E S  I N  T H E  1 2 - M O N T H  P E R I O D  *
I m p r o v e m e n t
P e r i o d
0 - 6  m o n t h s  * *
I -
C h a n g e  o f
c h e m o t h e r a p y
l u r i n g  t h e  p e r i o d
d u e  t o
d e t e r i o r a t i o n
T u b e r -
c u l o u s
d e a t h
T r e a t -
m e n t
s e r i e s
T o t a l
p a t i e n t s e x c e p -
t i o n a l
c o n s i -
d e r a b l e
m o d e r a t e s l i g h t
N o
c h a n g e
No. % No. %N o .        % No. % No. % No. %
_ _ _ _
P H
H I - 1
H I - 2
H
87 9 9 2 2
3 4
1 2
3 3
34 3 9 33 3 8 1 1
67 9 8 21 3 1 25 3 7 3 4
66 1 0 2 19 2 9 21 3 2 6 9
86 9 8 21 2 4 35 4 1
15 1 7
10 1 5
14 2 1
11 1 3 3 3
P H
H I - I
H I - 2
H
86 9 8 8 9 39 4 5 26 3 0 8 9 2 2
64 1 0 0
66 1 0 1
2 3
4 6
3 3
33 5 2 15 2 3 5 8 4 6
20 3 0 23 3 5 3 5 0 0
86 9 8 21 2 4 29 3 4 8 9 1 1
P H 85 1 0 0 61 7 2
H I - 1 63 1 0 0 38 6 0
H I - 2 64 1 0 1
0 0 0 0 4 5 1 3 15
0 0 0 0 3 5 1 4 22
0 0 0 0 0 0 1 0 16
0 0 0 0 1 1 9 11
37 5 8
H 79 9 9 49 6 2
D e t e r i o r a t i o n
s l i g h t m o d e r a t e
c o n s i -
d e r a b l e
N o . %  No. % No. %
t
N o . % No. %
0 0
1 1
1 2
4 5
1 1
5 8
1 4 21
1 5 17
1 1
0 0
1 2
3 3
1 1
0 0
1 2
3 3
0 0
0 0
1 2
3 3
1
2
2
2
0
0
0
2
1
1
1
5
1
3
3
2
0
0
0
2
1
2
2
6
0 0
2 3
0 0
1 1
1 1
0 0
1 2
4 5
0 0
0 0
0 0
0 0
O - 1 2  m o n t h s  * * *
0 0 1 1 0 0
0 0 4 6 0 0
0 0 1 3 20 0 0
0 0 1 1 14 0 0
5 6
3 5
3 5
4 5
6-12 months †
*  T h r e e  s e p a r a t e  a s s e s s m e n t s  o n  s t a n d a r d  r a d i o g r a p h s ,
* *  E x c l u d i n g  f o u r  p a t i e n t s  ( o n e  i n  e a c h  s e r i e s )  w h o  d i e d  o f  n o n - t u b e r c u l o u s  c o n d i t i o n s  a n d  f i v e  p a t i e n t s  ( 2  P H ,  2  H I - 1 ,  1  H I - 2 )  w h o  h a d  t h e i r  c h e m o t h e r a p y  c h a n g e d  o n
a c c o u n t  o f  t o x i c i t y .
* * *  E x c l u d i n g  f i v e  p a t i e n t s  ( 2  P H ,  1  H I - 1 ,  1  H I - 2 ,  1  H )  w h o  d i e d  o f  n o n - t u b e r c u l o u s  c o n d i t i o n s  a n d  e i g h t  p a t i e n t s  ( 2  P H ,  5  H I - 1 ,  1  H I - 2 )  w h o  h a d  t h e i r  c h e m o t h e r a p y
c h a n g e d  o n  a c c o u n t  o f  t o x i c i t y .
† E x c l u d i n g  o n e  p a t i e n t  ( P H )  w h o  d i e d  o f  a  n o n - t u b e r c u l o u s  c o n d i t i o n  a n d  t h r e e  p a t i e n t s  ( a l l  H I - i )  w h o  h a d  t h e i r  c h e m o t h e r a p y  c h a n g e d  o n  a c c o u n t  o f  t o x i c i t y .
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who deteriorated and had their chemotherapyimprovement. The progress of the other two series
changed during the period, or who died of tuber-was less satisfactory.
culosis, were 3%, 8%, 24%, and 28 %, respectively,
for the four series. Changes in cavitation
In the second six months the majority of theTable 9 presents the changes in cavitation for the
patients in all four series–namely, 72% of the12-month period, as assessed by Dr Raj Narain.
PH, 60 % of the HI-1, 58 % of the HI-2 and 62 % ofAs with cavitation on admission, cavitation at
the H series–showed no change radiographically.12 months was assessed on a single postero-anterior
Radiographic improvement occurred in a smallradiograph. The numbers of patients with extensive
proportion of the patients, and was usually slight.cavita ion are small, but the findings indicate that
To summarize, the progress of the PH seriesthe cavitation disappeared in about a quarter of
throughout the 12 months was very satisfactory andhem. Of the group of patients with moderate
the HI-1 series nearly achieved the same order ofcavitation initially, the cavitation had disappeared
CHANGES
Extent of
cavitation
on admission
to treatment
Extensive **
Moderate ***
Slight †
Total patients
with
cavitation
T A B L E  9
I N  C A V I T A T I O N  I N  T H E  1 2 - M O N T H  P E R I O D  I N  P A T I E N T S  W I T H  C A V I T A T I O N  O N  A D M I S S I O N
T O  T R E A T M E N T ,  A C C O R D I N G  T O  E X T E N T  O N  A D M I S S I O N  *
D i s a p - Cavities No
C a v i t i e s
p e a r a n c e  o f s m a l l e r  o r
l a r g e r  o r
c a v i t a t i o n  I f e w e r c h a n g e  
m o r e
I  
 n u m e r o u s
No. % No. %  No. %  No. %
P H 14 1 0 0 4 (29) ††    7 ( 5 0 ) 1 (7) 0 (0)
H I - 1 7 1 0 1 2 (29) 3 (43) 0 (0) 0 (0)
H I - 2 5 1 0 0 1 (20) 1 (20) 0 (0) 0 (0)
H 8 1 0 0 0 (0) 2 (25) 1 (12) 0 (0)
C h a n g e  o f
c h e m o t h e r a p y
d u r i n g  t h e  p e r i o d
 T u b e r c u l o u s
d u e  t o
d e a t h
d e t e r i o r a t i o n
N o . %    No. %
1 (7) 1 (7)
2 (29) 0 (0)
3 (60) 0 (0)
3 (38) 2 (25)
T o t a l
T r e a t m e n t p a t i e n t s
s e r i e s
No. %
*  A s s e s s m e n t  o n  s t a n d a r d  r a d i o g r a p h s  o n  a d m i s s i o n  t o  t r e a t m e n t  a n d  a t  1 2  m o n t h s .
* *  E x c l u d i n g  t h r e e  P H  p a t i e n t s ,  t w o  o f  w h o m  d i e d  o f  n o n - t u b e r c u l o u s  c o n d i t i o n s  a n d  o n e  w h o  h a d  h i s  c h e m o t h e r a p y  c h a n g e d
o n  a c c o u n t  o f  t o x i c i t y .
* * *  E x c l u d i n g  t w o  p a t i e n t s  ( 1  H I - 1 ,  1  H )  w h o  d i e d  o f  n o n - t u b e r c u l o u s  c o n d i t i o n s  a n d  f i v e  p a t i e n t s  ( 4  H I - 1 ,  1  H I - 2 )  w h o  h a d  t h e i r
c h e m o t h e r a p y  c h a n g e d  o n  a c c o u n t  o f  t o x i c i t y .
†  E x c l u d i n g  o n e  p a t i e n t  ( H I - 2 )  w h o  d i e d  o f  a  n o n - t u b e r c u l o u s  c o n d i t i o n  a n d  t w o  p a t i e n t s  ( 1  P H ,  1
t h e r a p y  c h a n g e d  o n  a c c o u n t  o f  t o x i c i t y .
H I - 1 )  w h o  h a d  t h e i r c h e m o -
† †  P e r c e n t a g e s  b a s e d  o n  f e w e r  t h a n  2 5  o b s e r v a t i o n s  a r e  e n c l o s e d  i n  p a r e n t h e s e s ,  a s  a n  i n d i c a t i o n o f  t h e  s m a l l  t o t a l s .
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in 63 % of 41 PH, 52% of 31 HI-1, 39 % of 38 HI-2
and 38 % of 45 H patients; in 5 % of the PH, 6%
of the HI-1, 32% of the HI-2 and 31% of the H
series there were increases in cavitation, changes of
chemotherapy due to deterioration, or tuberculous
deaths, The progress of patients with slight cavita-
tion was very similar in all four series, the cavitation
disappearing in more than 80% of the patients.
It may be concluded that there was evidence of
differences between the four treatment series in
patients with moderate cavitation, but little difference
between them for patients with slight cavitation.
The numbers of patients with extensive cavitation
are too small to permit firm conclusions. Eight
PH, one HI-1, five HI-2 and eight H patients had
no cavitation on admission to treatment. At
12 months two of these patients (both H) had
cavitation which was graded as slight.
BACTERIOLOGICAL
Smear and culture results
The results of the smear and culture examination
of single collection specimens of sputum each month
are set out in Table 10. The findings, being based
on single monthly cultures (a usual rhythm of
investigation of tuberculous patients under active
treatment), are suitable for comparison with those
of other studies and, in particular, with the findings
of an earlier study from this Centre (Tuberculosis
Chemotherapy Centre, 1959). Further investigations
(to be reported elsewhere) suggest that the bacilli
in specimens yielding smear-positive but culture-
negative results were non-viable in all four treat-
ment series, confirming findings already reported
for patients on the PH regimen (Tuberculosis
Chemotherapy Centre,1959). Such results have
therefore been regarded as bacteriologically negative.
Table 10 shows that there was a rapid decline in the
proportion of patients with positive cultures in all
the series; by three months 78 % of 81 PH, 64% of
69 HI-1, 55 % of 64 HI-2 and 43 % of 82 H patients
yielded a negative culture. At six months the
proportions had increased to 88 %, 71%, 58 % and
49 %, respectively. There was comparatively little
change during the rest of the period and at 12
months the proportions were 90% for the PH series,
76 % for the HI-1, 59 % for the HI-2 and 51% for
the H series.
As described above (see page 540), multiple speci-
mens were examined at monthly intervals for each
patient. At three, six, nine and 12 months the
average number of test results per patient ranged
from 2.6 to 2.8. At each of these four monthly
examinations, the numbers of patients all of whose
cultures were negative were very similar to the
number  culture-negative on a single collection speci-
men. The data have not been tabulated here.
However, the percentage of patients with at least
on  positive culture result is shown for the four treat-
ment series each month in Fig. 1.
Fig. 2 shows, for each of the four treatment series
separately, the results of the multiple-culture exami-
nations each month for the patients who continued
on the prescribed chemotherapy, together with the
changes of chemotherapy due to deterioration and
the eaths due to tuberculosis.
Isoni zid sensitivity
The results of the isoniazid-sensitivity tests are
set out in Table 11. Each of the three series of
patients treated with isoniazid alone already showed
some resistant cultures at one month. Thus, 12%
of the positive cultures tested from patients in the
HI-1 series, 13 % in the HI-2 and 15 % in the H
series were resistant. At three months the propor-
tion  of the positive cultures tested which were
resistant were 9% for the PH series, 78% for the
HI-1, 79 % for the HI-2 and 75 % for the H series ; at
six months the corresponding proportions were 80 %,
100%, 100 % and 97 % respectively (only three of
90 strains in the four treatment series combined were
sensitive). In the second six months nearly all the
positive cultures were resistant, and at 12 months
52 of the 53 positive cultures from the four treat-
ment series combined were resistant, the exception
being one strain in an HI-1 patient. No patient in
any of the four treatment series remained consistently
bacteriologically positive with isoniazid-sensitive
or nisms throughout the 12 months. Thus, no
iso iazid-sensitive strains were found after the third
month of treatment in any of the 23 patients (4 HI-1,
5 HI-2, 14 H) who were bacteriologically positive at
each of the 12 months.
In order to compare the potential public health
risk i  the four treatment series, as represented by
excretors of isoniazid-resistant organisms, the patients
who had their chemotherapy changed owing to
deterioration have been added to those who con-
tinued on the allocated chemotherapy and yielded
resistant strains (Table 11, last column), since all
the 35 patients who deteriorated had resistant strains
when their chemotherapy was changed. In this
way a consolidated total of patients with resistant
P R E S E N C E  O F  T U B E R C L E  B A C I L L I  I N  S I N G L E  C O L L E C T I O N  S P E C I M E N S  O F  S P U T U M  T A K E N  F R O M  P A T I E N T S  A T  M O N T H L Y  I N T E R V A L S
T r e a t m e n t T o t a l
s e r i e s p a t i e n t s  *
M o n t h s
a f t e r  s t a r t
o f
c h e m o -
t h e r a p y
0
P H
H I - 1
H I - 2
H
P H
H I - 1
H I - 2
H
90 – – 26 2 5
70 – – 2 8 1 7
6 8 – – 2 5 2 2
87 – 3 2 3 1
8 91 4
1 9
1 3
1 1
1 4 7 5
0 2 2 2
0 1 2 3
0 4 2 5
0 0
2 3
2 2
89 0 0 1 1 1 2 3
6 8 0 0 3 13 2 2
66 0 0 0 8 2 1
85 2
I
O 1 1 5 2 2
1 5 1 4 1 2
0 0 1 0 12
0 0 13 10
0 2 1 5 1 6
2 2 25
8 12
1 4 21
1 2 14
I
P H 86 86
H I - 1 6 66 6
H I - 2 6 36 3
H 86 86
0 0 0
0 0 0
0 0 111 4
22 0  3 9
1 0 00
0 0 222 6
00 0 222 5
22 00 777 7
3
2
4
9
0
6
5
7
1 71 7
1 91 9
1 41 4
1 71 7
P H
H I - 1
H I - 2
H
88
99
1 31 3
99
0 1 5 1 4
10
0 0 3 9
0 4 8 1 2
5
5
4 6 53
3 1 47
3 2 51
3 1 36
6 3 78
4 4 64
3 5 55
3 5 43
8 18 1
69 69
6 46 4
8 28 2
3
P H 8 3 1 0 0 0 3
H I - l 66 0 0 2 4 10
H I - 2 66 1 0 3 7 7
H 8 2 3 1 6 7 1 5
0 0 1 6 72 8 7
0 1 3 3 4 3 6 5
0 0 5 3 4 0 61
0 O 4 5 4 1 50
4
5
0 0 4 4 75 8 8
0 1 1 2 5 1 7 7
0 1 2 2 4 0 6 2
0 0 2 4 3 9 4 9
P H
H I - I
H I - 2
H
0
5
6
13
85 1 0 1
66 0 2 3
64 3 9
80 6 11

TABLE 11
R E S U L T S  O F  I S O N I A Z I D - S E N S I T I V I T Y  T E S T S  I N  T H E  1 2 - M O N T H  P E R I O D  *
I
P a t i e n t s  c u l t u r e - p o s i t i v e  w i t h  s e n s i t i v i t y  t e s t s
C u l t u r e -
n e g a t i v e
( n o  s e n -
sitivity
t e s t
p o s s i b l e )
t o t a l
M o n t h s
a f t e r T r e a t -
s t a r t  o f m e n t
c h e m o - s e r i e s
t h e r a p y
I
P H
H I - 1
H I - 2
90
69
67
H 83
P H 86
H I - 1 66
H I - 2 6 3
H 84
PH       8 6
H I - 1 69
H I - 2 67
H 84
p o s i t i v e
b u t  n o t o t a l
 s e n s i t i v e r e s i s t a n t
s e n s i t i v i t y r e s u l t s
t e s t  r e s u l t a v a i l a b l e n o  g r o w t h
 0 . 2  µ g / m l
a v a i l a b l e
( B )
g r o w t h
o n  5  b u t
n o t  o n  5 0
µ g / m l
g r o w t h
o n  5 0
µ g / m l
r e s i s t a n tT o t a l
p a t i e n t s  * *
( A )
0
3
2 * * *
2
0 0
2 1
0 3
4 3
I -
0 0 0
7 1 3
5 5 * * * 2
10† 8 6
deteri-                                               N o . % of B
( C )
0 0
7 12
7 13
1 1 15
1 2
1 3 35
1 7 46
3 1 56
I
0  0
0 7
0 7
0 1 1
0 1
0 13
0 17
0 3 1
0 2
0 2 1
0 2 2
0 36
0 5
0 2 3
0 2 4
1 3 6
5 (50)
2 3 92
2 4 92
3 5 97
9 (75) 0 9
16 (100) 1 1 7
2 3 85 0 2 3
37 100 2 3 9
2 1
9
1 0
9
67
57
53
7 3
67
50
4 6
6 2
44
24
2 0
2 4
22 2 0
2 7 6
2 8 6
48 1 2
0
10
10
44
10
25
35
48
0 0 0 2 (9) †††
9 5 * * * 6 2 1 78
7 6 4 22 79
18† 7 9 3 6 75
3 8
29
26
2 6
6 3
4 1
3 6
36
77
44
3 9
43
7 3
50
3 8
4 1
1††
1 1 5
8 8
11† 1 0
1
3
6
9 * * *
10
25
2 6
3 6
12
P H 87
H I - 1 6 9
H I - 2 66
H 8 2
P H 86
H I - 1 6 8
H I - 2 66
H 82
16
27
3 7
1 1 0
1 1 8
5
              PH 8 6 8 (80) 0 8 9
1 8 (100) 1 1 9 28
2 3 (100) 1 2 4 37
3 8 97 4 42 51
75
                  47
39
39
HI-1  67
6
HI-2  65
H 83
04 6
4 9
1 1 12
7
1 8
20
39
1†† 0 5
3 4 18
4 * * * 9 1 8
8 1 6 36
T A B L E  I I  ( c o n t i n u e d )
P H 85 7 6
H I - 1 6 6 46
H I - 2 6 4 39
H 8 3 3 7
8 9
1 9 29
25 39
4 5 54
6 7
1 9 29
2 4 37
4 3 52
6 7
1 7 26
2 5 38
45 54
6 7
1 7 26
2 2 34
42 51
(88) 1
(95) 1
(100) 5
100 6
(100)
(100)
(90)
97
(71) 1
(100) 2
(100) 9
100  9
1
1
1
7
0
1
0
4
P H 8 5
H I - 1 6 6
H I - 2 65
H 82
0 8
0 1 9
0 2 0
1                         39
0
5
8
15
P H 85
H I - 1 66
H I - 2 65
H 8 3
79 0 5 0
4 7 0 18 0
3 7 2 2 0 2
3 5 3 37 1
77 0 7 2
49 0 15 0
40 0 1 6 0
35 3 3 6 0
78 1 5 0
47 1 1 5 0
4 1 1 1 3 1
38 3 3 0 0
8
5
15
16
36
 2
1 0
1 2
 4
1 2
1 3
8 10
1 7 2 7
22 34
42 51
 1 7 8
5 16 25
1 4 2 5 38
15 3 9 47
- -
P H 85
H I - 1 6 5
H I - 2 6 5
H 83
1 1 5 (100)
6 5 15 (100)
2 7 1 2 (92)
10 1 2 3 0 100
P H  84  75 1 2 1 7 (100)
3 5 13 (100)
6 2 1 0 (1OO)
9 1 2 29 100
7 0
13 0
1 0 0
2 9 0
H I - 1 64
H I - 2 64
H 8 3
4 7 0
4 2 0
P H 8 4 7 7
H I - 1 6 4 47 0
H I - 2 6 5 40
H  83  44
 0
0
0 1 6 (100)
5 2 1 1 (92)
3 6 1 1 (100)
5 1 2 2 4 (100)
6 0 2 3
12 1 1 3
1 1 0 0 2
24 0 1 6
12
*  A l l  p a t i e n t s  h a d  s t r a i n s  s e n s i t i v e  t o  i s o n i a z i d  b e f o r e  t r e a t m e n t .
** All the patients who died are excluded after their death and patients who had their chemotherapy changed on account of toxicity are excluded after the change; Patients
w h o  h a d  t h e i r  c h e m o t h e r a p y  c h a n g e d  o w i n g  t o  d e t e r i o r a t i o n  r e m a i n  i n  t h e  t o t a l s  t h r o u g h o u t  ( s e e  p a g e s  5 4 8 ,  5 4 9 ,  5 5 3  a n d  5 5 8 ) .
* * *  I n c l u d e s  o n e  s t r a i n  w i t h  n o  t e s t  r e s u l t  o n  5 0  µ g / m l .
† I n c l u d e s  o n e  s t r a i n  w i t h  n o  t e s t  r e s u l t  o n  5  µ g / m l .
†† N o  t e s t  r e s u l t  o n  5 0  µ g / m l .
††† Percentages based on fewer than 25 observations are enclosed in parentheses, as an indication of the small totals.
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FIG. 1
PERCENTAGE OF PATIENTS EACH MONTH WITH AT LEAST ONE POSITIVE
CULTURE RESULT FROM MULTIPLE BACTERIOLOGICAL SPECIMENS
(SPUTUM AND LARYNGEAL SWABS)
D U R A T I O N  O F  T R E A T M E N T  ( M O N T H S )
strains was obtained. It should be noted that (in
contrast to all the other tables) the patients who
died of tuberculosis have been excluded after their
death from the totals in Table 11, since they then
no longer represented a public health risk. At
three months the total of patients with resistant
strains represented 2 % of the PH, 30% of the
HI-1, 33% of the HI-2 and 43 % of the H series.
From three to 12 months there was little change
in these proportions.Thus, at 12 months 8 %
of the PH, 25 % of the HI-1, 38 % of the HI-2
and 47 % of the H series had resistant organisms.
It may be concluded that the potential public
health risk from excretors of isoniazid-resistant
organisms was appreciable in the HI-1, HI-2 and
H series from early in the period of treatment, and
continued for the rest of the 12 months. (The
possibility that these resistant organisms are of
lowered infectivity will be considered in later publica-
tions relating to the attack rate of tuberculosis in
the family contacts).
Response to trentmznt during the 12 months
Table 12 presents a classification of all the patients
at 12 months, based primarily on the bacteriological
response to treatment (see also Fig. 3). A patient’s
disease was classified as bacteriologically quiescent
if all the cultures for at least the last three monthly
examinations (that is, those at 10, 11 and 12 months)
were negative. Those pstients who, following at
least three months of culture negativity, yielded an
isolated positiveculture at one of the last three
monthly examinations have been classified as bac-
ter ologically of doubtful status. Patients whose
s tum was culture-positive on at least two occasions
at he examinations for the last three months were
classified as bacteriologically relapsed, provided that
they had previously yielded only negative results
for all the cultures at three consecutive monthly
examinations. Patients who never had a period of
three consecutive months of bacteriological negativ-
ity were classified as bacteriologically active, as were
the patients who deteriorated radiographically or
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clinically, and so had their chemotherapy changed.seven and 10 months in 7 % of the 74 PH, 9%
In all, 86 % of the PH patients, 67 % of the HI-1,of the 43 HI-1, 11% of the 37 HI-2 and 26 % of
56% of the HI-2 and 44% of the H patients werethe 38 H patients with quiescent disease.
classified as bacteriologically quiescent at 12 months;Pa ients with an unfavourable response were
and a further 5 % of the PH, 6 % of the HI-1 and 2 %defined as those who had relapsed bacteriologically
of the HI-2 series were bacteriologically of doubtfulr who had active disease (including those who had
status. There were also differences between thetheir chemotherapy changed owing to deterioration)
series in the proportions of patients who attainedor who died of tuberculosis.The proportions with an
bacteriological quiescence between the seventh and theunfavourable response were 9 % for the PH, 27 % for
tenth months of treatment. Among the patients whosehe HI-1, 42 % for the HI-2 and 56 % for the H
disease attained bacteriological quiescence, the periods ries. The differences between the PH and the
of persisting bacteriological negativity started betweenother three series are statistically highly significant
FIG. 2
PERCENTAGE OF PATIENTS EACH MONTH WHO WERE BACTERIOLOGICALLY NEGATIVE,
BACTERIOLOGICALLY POSITIVE, WHOSE TREATMENT HAD BEEN CHANGED OWING
TO DETERIORATION OR WHO DIED OF TUBERCULOSIS
D U R A T I O N  0 F  T R E A T M E N T  ( M O N T H S )
D U R A T I O N  O F  T R E A T M E N T  ( M O N T H S )
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T A B L E  1 2
C L A S S I F I C A T I O N  O F  A L L  T H E  P A T I E N T S  A T  T H E  E N D  O F  1 2  M O N T H S
A C C O R D I N G  T O  T H E I R  R E S P O N S E  T O  T R E A T M E N T
C l a s s i f i c a t i o n  a t  t h e  e n d  o f  1 2  m o n t h s P H
Patients with bacteriologically quiescent disease :
t h a t  i s ,  p a t i e n t s  w h o s e  c u l t u r e s  w e r e  a l l  n e g a t i v e  f o r  a t
l e a s t  t h e  l a s t  t h r e e  m o n t h l y  e x a m i n a t i o n s - i . e . ,  a t  1 0 ,  1 1
a n d  1 2  m o n t h s
Total patients with bacteriologically quiescent disease  . . . . . . . . . . . . . . . 74 86 4 3 67 37 56 38 4 4
T r e a t m e n t  s e r i e s
No. %
1 4
1 0
5
3
0
1
- -
Patients with disease of bacteriologically doubtful status :
that is, patients whose cultures were all negative at three or more consecutive
m o n t h l y  e x a m i n a t i o n s  b u t  w h o  p r o d u c e d  a n  i s o l a t e d  p o s i t i v e  c u l t u r e  a t  o n e
o f  t h e  l a s t  t h r e e  m o n t h l y  e x a m i n a t i o n s - i . e . ,  a t  1 0 ,  1 1  o r  1 2  m o n t h s  .  .  .  . 4 5
Patients with bacteriologically relapsed disease :
that is, patients whose cultures were all negative at three or more consecutive
m o n t h l y  e x a m i n a t i o n s ,  b u t  w h o  p r o d u c e d  t w o  o r  m o r e  p o s i t i v e  c u l t u r e s  i n
t h e  l a s t  t h r e e  m o n t h l y  e x a m i n a t i o n s - i . e . ,  a t  1 0 ,  1 1  a n d  1 2  m o n t h s  .  .  .  .  . 4 5
Patients with bacteriologically active disease :
t h a t  i s ,  (a) p a t i e n t s  w h o s e  c u l t u r e s  w e r e  n e v e r  a l l  n e g a t i v e  a t  t h r e e  c o n -  
s e c u t i v e  m o n t h l y  e x a m i n a t i o n s  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  . 2 2
or (b) p a t i e n t s  w h o  d e t e r i o r a t e d  a n d  h a d  t h e i r  c h e m o t h e r a p y  c h a n g e d 1 7
4 6 1 2 0 0
2 3 5 8 5 6
T o t a l  p a t i e n t s  w i t h  b a c t e r i o l o g i c a l l y  r e l a p s e d  o r  a c t i v e  d i s e a s e  .  .  .  .  .  .  .  7 8            1 7         27
I
T u b e r c u l o u s  d e a t h s  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  . 1 1 0 0
27 41 45 52
1 2 3 3
T o t a l  . .  . .  . .  .  . .  .  .  .  .  .  . .  .  .  . . . .  .  .  . .  . .  .  . . . . . . 8 6 100 6 4 103       66 101      86 99
I
P a t i e n t s w h o h a d t h e i r c h e m o t h e r a p y c h a n g e d o n a c c o u n t o f t o x i c i t y . . . .  2 – 5 – 1 – 0 –
N o n - t u b e r c u l o u s  d e a t h s  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .   2 -
I
1 - l -  l -
I I
A l l  p a t i e n t s  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  9 0  – 70          – 66 – 87 –
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the other 18 patients had bacteriologically qurescent
disease.
Change of chemotherapy
due fo deterioration
Active bacteriologically
VI. INFLUENCE OF THE VIRULENCE OF THE INFECTING ORGANISMS
ON THE RESULTS OF TREATMENT
It has been shown (Dhayagude & Shah, 1948;
Frimodt-Møller, Mathew & Barton, 1956; Mitchison
et al., 1960) that, unlike sensitive strains of tubercle
bacilli from previously untreated patients in Great
Britain, pretreatment sensitive strains from Indian
patients have a wide range of virulence in the guinea-
 pig. It was therefore important in the present study
to measure the virulence of the patients’ organisms
  before the start of treatment, and to investigate the
response to treatment in relation to this factor.
The pretreatment virulence was measured in 281
(89 %) of the 315 patients in the main analysis–
namely, 82 (91%) of the PH, 63 (90 %) of the HI-1,
60 (88 %) of the HI-2 and 76 (87 %) of the H patients.
VIRULENCE OF TUBERCLE BACILLI IN THE GUINEA-PIG
The measure of virulence used was based on the
rate of progression of the disease in the guinea-pig,
and has been described in detail by Mitchison et al.
(1960). In brief, 1 mg moist weight of a pretreat-
ment culture of tubercle bacilli was inoculated intra-
muscularly into each of two guinea-pigs, one of
which was killed at six weeks and the other at
12 weeks. If either died before six weeks it was
counted as a 6-week animal and the remaining
guinea-pig as the 12-week animal. At post-mortem
examination the total extent of tuberculous disease
in the spleen, liver, lungs and local glands was
assessed as a score ranging from 0 to 100. The ratio
of the score to the survival time in days was deter-
mined for each guinea-pig. The index of virulence
employed was the mean of the ratios for the two
ui ea-pigs.
PRETREATMENT COMPARISON BETWEEN THE FOUR SERIES
The distributions of the index of virulence for the
pretreatment strains in the four series are shown in
Table 13. They were, in general, similar for the PH,
HI-1 and H series, 30%, 27 % and 30 % of the
patients, respectively, having organisms with high
virulence (index of 0.8 or more). The HI-2 series,
h wev r, had a much smaller proportion (13 %) of
str ins with high virulence. The position is sum-
marized by the average indices of virulence, which
were 0.639 for the PH series, 0.584 for the HI-1,
0.498 for the HI-2 and 0.658 for the H series. The
differences between the means of the four series are
unexpectedly large (P<0.05). In view of the sub-
s antial apparent advantage to the HI-2 series in
terms of initial virulence of the organisms, it was
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T A B L E  1 3
V I R U L E N C E  I N  G U I N E A - P I G S  O F  T H E  S T R A I N S
O F  T U B E R C L E  B A C I L L I  F R O M  T H E  P A T I E N T S  O N
A D M I S S I O N  T O  T R E A T M E N T
I n d e x  o f
v i r u l e n c e
o . o -
0 . 2 -
0 . 4 -
0 . 6 -
0 . 8 -
1 . 0 -
1.2-
1.4-
1 . 6  o r  m o r e
P H
No. % No. % No. % No. %
6 7 2 3 7 1 2 3 4
16 2 0 22 3 5 23 3 8 16 2 7
23 2 8 15 2 4 12 2 0 20 2 6
12 1 5 7 1 1 10 1 7 14 1 8
11 1 3 9 1 4 2 3 9 1 2
7 9 4 6 3 5 6 8
4 5 3 5 0 0 6 8
2 2 1 2 3 5 2 3
1 1 0 0 0 0 0 0
T o t a l  p a t i e n t s  *    82   100
A v e r a g e  i n d e x 0 . 6 3 9
H I - 1
6 3  1 0 0
0 . 5 8 4
H I - 2
6 0  1 0 0
H
7 6  1 0 0
0 . 4 9 8  0 . 6 5 8
* T h e  v i r u l e n c e  w a s  n o t  d e t e r m i n e d  f o r  s t r a i n s  f r o m  3 4
p a t i e n t s  ( 8  P H ,  7  H I - 1 ,  8  H I - 2 ,  1 1  H ) .
necessary to examine whether this reflected any other
pretreatment difference and whether it had influenced
the response to treatment in this series of patients.
VIRULENCE OF THE ORGANISMS IN RELATION
TO OTHER CLINICAL FEATURES AT THE START
OF TREATMENT
The full findings on the relationship between the
virulence of the infecting organisms and the clinical
condition of the patient at the start of treatment will
be published separately. It is sufficient to note here
that there were no important associations between
pretreatment virulence and a number of the clinical
aspects of the disease at the start of treatment,
including the total extent of the radiographic lesion,
the extent of cavitation, and the presence of tubercle
bacilli in the sputum.In other words, the lower
average virulence of the organisms in the patients
in the HI-2 series was an independent finding. There
was no evidence of an association of pretreatment
virulence with other factors which might influence
the progress of the patients during treatment.
PROGNOSTIC IMPORTANCE OF THE VIRULENCE
OF THE ORGANISMS IN THE GUINEA-PIG
The full findings on the prognostic importance of
the virulence of the strains in the guinea-pig will
also be published separately. In brief, there was a
tendency for patients with organisms of low virulence
at the start of treatment to make more satisfactory
progress than patients with organisms of high
virulence. This tendency was most apparent in
treatment with HI-2 and H, the least effective regi-
mens. Even with these regimens, however, the asso-
ciation was not strong.
In view of this slight association, and the sub-
stantial differences in pretreatment virulence be-
tween the series, it was decided that it would be
valuable to study the influence of these differ-
ences on the results of treatment, particularly in
order to define more precisely the position of
the HI-2 regimen in relation to the HI-1 and H
regimens.
PROCEDURE FOR STUDYING THE EFFECT OF
THE PRETREATMENT DIFFERENCES IN VIRULENCE
The approach used was statistical standardization
of the results of treatment to allow for the pretreat-
ment differences in virulence. The principle under-
lying this technique is a comparison of the progress
of patients in the four treatment series who had
similar indices of virulence at the start of treatment.
Further details of the approach have been given in an
earlier report (Tuberculosis Chemotherapy Centre
1959).
Three measures of radiographic and three of
bacteriological response were standardized for dif-
ferences in pretreatment virulence. The measures of
radiographic response were: (1) the percentage of
patients showing considerable or exceptional im-
provement in the period 0-6 months; (2) the cor-
responding percentage for the period 0-12 months;
and (3) the percentage of patients with cavitation at
the start of treatment in whom the cavitation had
disappeared at 12 months. The measures of bacterio-
logical response were: (1) the percentage of patients
with a n gative culture on a single collection speci-
men at six months; (2) the corresponding percentage
at 12 months; and (3) the percentage of patients with
bact riologically quiescent disease (or disease of
doubtful status) at the end of 12 months, according
to the definition adopted in this report (see page 558)
The standardized and the unstandardized percen
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P E R C E N T A G E S  O F  P A T I E N T S  S H O W I N G  F A V O U R A B L E  R A D I O G R A P H I C  A N D  B A C T E R I O L O G I C A L  R E S P O N S E S ,
S T A N D A R D I Z E D  F O R  P R E T R E A T M E N T  D I F F E R E N C E S  I N  V I R U L E N C E  O F  T H E  O R G A N I S M S
R a d i o g r a p h i c  r e s p o n s e B a c t e r i o l o g i c a l  r e s p o n s e
 P e r c e n t
N a t u r e  o f
r e s p o n s e
P H 41                      42
H
I
2 7                28
P H 5 6 I 57
0 - 1 2
m o n t h s
H I - 1 5 5 56
H I - 2 3 6 32
H 2 8 30
tages for all six assessments are shown in Table 14.
(The unstandardized percentages are based on smal-
ler totals and differ slightly from the corresponding
percentages in Tables 8, 9, 10 and 12, because pre-
    treatment virulence data were not available for all
      the patients.)
Radiographic response
A comparison of the standardized and the un-
standardized percentages shows that, for all practical
purposes, only the results for the HI-2 series were
affected by standardization for differences in pre-
treatment virulence; each of the percentages for this
series fell slightly, so that the results became very
similar to those for the H series (Table 14). The
standardized percentages showing considerable or
exceptional radiographic improvement in the 0-12-
month period were 57 %in the PH series, 56 % in the
HI-1, 32% in the HI-2 and 30% in the H series.
N a t u r e  o f M o n t h   T r e a t m e n t
r e s p o n s e s e r i e s
P H
H I - 1
N e g a t i v e
c u l t u r e  o n
a  s i n g l e
c o l l e c t i o n
s p e c i m e n
6 
H I - 2
I H
P H
1 2 H I - 1
H I - 2
 H
P H
H I - 1
1 2
H I - 2
 H
U n s t a n d a r d -
i z e d
p e r c e n t a g e
P e r c e n t a g e
s t a n d a r d i z e d
f o r
p r e t r e a t m e n t
d i f f e r e n c e s
i n  v i r u l e n c e
87 87
74 73
54 46
48 50
89 90
78 76
55 49
50 57
90
75
53
43
90
73
47
44
Bacteriological response
The effect of standardization upon the measures
of bact riological response was similar to the effect
on radiographic response; there was little alteration
in the percentages in the PH, HI-1 and H series, but
those for the HI-2 series fell to about the level of
those for the H series (Table 14). The standardized
percentages of patients whose disease had attained
bacteriological quiescence (or who had disease of
bacteriologically doubtful status) at 12 months were
90 % in the PH series, 73 % in the HI-1, 47 % in the
HI-2 and 44% in the H series. The standardized
percentages for unfavourable response (for defini-
tion, see page 559) were 10 %, 27 %, 53 % and 56 %,
respectively, for the four series. It may be concluded
that, when allowance was made for the pretreatment
differences in the virulence of the organisms, the
responses of patients in the HI-2 and H series,
already similar, became almost identical.
564 TUBERCULOSIS CHEMOTHERAPY CENTRE
VII. PROGNOSTIC VALUE OF VARIOUS FACTORS ON ADMISSION TO TREATMENT
It is important to investigate which features of
the disease at the start of treatment were associated
with an unfavourable response to treatment, and
this has been studied in relation to various factors–
namely, the age (estimated), the ESR, the extent
of cavitation, the total extent of the disease, the
number of lung zones involved in disease and the
bacterial content of the sputum. The findings are
set out in Table 15. Unfavourable response, it will
be recalled (page 559), comprises tuberculous death;
bacteriologically active disease at 12 months, includ-
ing change of chemotherapy due to deterioration;
or bacteriologically relapsed disease at 12 months.
ESTIMATED AGE
There was no definite association between the
estimated age and an unfavourable response in any
of the four treatment series.
ERYTHROCYTE SEDIMENTATION RATE
In the PH series there was an association between
the ESR and unfavourable response, 13 % of 60
patients with an ESR of 51 mm or more having
an unfavourable response, compared with none of
26 with lower ESRs (P= 0.05). The association,
although also present, was weaker in the HI-1 and
H series; there was no evidence of an association
in the HI-2 series.
CAVITATION
Extensive cavitation was an unfavourable prog-
nostic sign in all four series, although this was less
so in the PH than in the other three series. In the
HI-1, HI-2 and H series moderate cavitation was
also relatively unfavourable when compared with
slight or no cavitation.Thus, 29 % of 31 HI-1,
50% of 38 HI-2 and 60% of 45 H patients with
moderate cavitation had an unfavourable response,
compared with 12 % of 26 HI-1, 22 % of 23 HI-2
and 39% of 33 H patients with slight or no cavita-
tion. It is noteworthy that even for patients with
slight or no cavitation the H regimen and, to a
lesser extent, the HI-2 regimen were not satisfactory.
TOTAL EXTENT OF DISEASE
In all four treatment series the proportion of
patients with gross or extensive disease who had an
unfavourable response to treatment was higher than
the corresponding proportion for the patients with
less extensive disease. It will be observed that one
of three HI-2 and two of five H patients with slight
disease responded unfavourably. All the 12 patients
with trivial disease responded satisfactorily.
NUMBER OF LUNG ZONES INVOLVED IN DISEASE
There was no association between the number of
lung zones involved in disease and an unfavourable
response in the PH, HI-1 and HI-2 series but there
was a slight association in the H series; in all four
series unfavourable responses occurred even in
patients with only two lung zones involved in disease.
BACTERIAL CONTENT OF THE SPUTUM
Of the 27 PH patients with 3-plus positive smear,
19% had an unfavourable response compared with
5 % of 59 PH patients with lower gradings. The
corresponding findings for the other three series
were 44 % of 25 compared with 15 % of 39 for the
HI-1 patients, 56% of 25 compared with 34 % of
41 for the HI-2 patients and 59% of 32 compared
with 54% of 54 for the H patients. It may be
co cluded that in the PH, HI-1 and HI-2 series
patients with a bacterial content of sputum
graded as 3-plus fared less well than patients with
specimens graded 2-plus, 1-plus or negative. For
the H series, only the patients with a negative
smear result gave evidence of a satisfactory response.
T A B L E  1 5
U N F A V O U R A B L E  R E S P O N S E  T O  T R E A T M E N T  A C C O R D I N G  T O  V A R I O U S  F A C T O R S  O N  A D M I S S I O N *
P H H I - 1 H I - 2 H A l l  s e r i e s
F a c t o r  o n
a d m i s s i o n  t o u n f a v o u r a b l e u n f a v o u r a b l e u n f a v o u r a b l e u n f a v o u r a b l e u n f a v o u r a b l e
treatment                       t o t a l r e s p o n s e  * * t o t a l r e s p o n s e t o t a l r e s p o n s e t o t a l r e s p o n s e t o t a l r e s p o n s e
p a t i e n t s p a t i e n t s p a t i e n t s p a t i e n t s                                                                                      patients
No. %  No. % No. %      N o .     % 
No. %
I
12-24
E s t i m a t e d  a g e 2 5 - 3 4
( y e a r s )
3 5 - 4 4
4 5 - 5 4
55 or more
E S R 101 or more
( m m  i n 51- 100
1  h o u r )
2 1 - 5 0
O - 2 0
1 0 1 33
N u m b e r
o f  l u n g
z o n e si n v o l v e d
i n  d i s e a s e
s p e c i m e n )
T o t a l  p a t i e n t s 86 8 9 6 4 1 7 27 6 6 28 4 2 86 48 5 6 302
*  E x c l u d i n g  t h e  f i v e  p a t i e n t s  w h o  d i e d  o f  n o n - t u b e r c u l o u s  c o n d i t i o n s  a n d  t h e  e i g h t  p a t i e n t s  w h o  h a d  t h e i r  c h e m o t h e r a p y  c h a n g e d  o n  a c c o u n t  o f  t o x i c i t y .
* *  T h a t  i s ,  t u b e r c u l o u s  d e a t h ;  b a c t e r i o l o g i c a l l y  a c t i v e  d i s e a s e  a t  1 2  m o n t h s ,  i n c l u d i n g  c h a n g e  o f  c h e m o t h e r a p y  o w i n g  t o  d e t e r i o r a t i o n  ; o r  b a c t e r i o l o g i c a l l y  r e l a p s e d
d i s e a s e  a t  1 2  m o n t h s .
* * *  P e r c e n t a g e s  b a s e d  o n  f e w e r  t h a n  2 5  o b s e r v a t i o n s  a r e  e n c l o s e d  i n  p a r e n t h e s e s ,  a s  a n  i n d i c a t i o n  o f  t h e  s m a l l  t o t a l s .
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VIII. FURTHER BACTERIOLOGICAL FINDINGS
PAS SENSITIVITY
In an earlier report (Tuberculosis Chemotherapy
Centre, 1959) the results of PAS-sensitivity tests
were expressed as resistance ratios–that is, as the
minimal drug concentration inhibiting growth of
the test strain, divided by the minimal drug con-
centration inhibiting growth of the standard sensitive
control strain, H37Rv.“ Growth ” was defined as
20 or more colonies, both for the test strain and for
strain H37Rv. In that report a patient was regarded
as harbouring resistant organisms before treatment
“ . . .if any test yielded a resistance ratio of more
than 8, or if there were two tests, one of which
yielded a resistance ratio of 8 and the other 4 or
more, or if three resistance ratios of 4 were obtained
from among the tests on the two pretreatment
cultures and the two repeat tests on those cultures ”.
According to these definitions, no less than 22%
of the 338 patients in the present study, who, as
far as is known, had had no (or less than two weeks’)
previous chemotherapy, had PAS-resistant strains
before the start of treatment, compared with less
than 3% of the patients in the earlier study. This
finding makes it evident either that a much higher
proportion of patients harbouring PAS-resistant
strains was admitted to the present study, or that
the technique of performing the tests was different
in the two studies. The former explanation is very
unlikely since the proportions of patients with
primarily isoniazid- or streptomycin-resistant strains
were not notably different for the two studies, there
being 3.8 % resistant to isoniazid and 2.3 % to strepto-
mycin in the earlier study and 5.9% (section XII)
and 3.3 % (see below), respectively, in the present
study. In view of these small increases between
the two studies some increase may also have occurred
in the percentage of patients with PAS-resistant
strains admitted to treatment in the present study,
but it would seem most unlikely that a tenfold
increase had taken place; there is no reason to
believe that chemotherapeutic practice in Madras
has recently changed to such an extent as could
account for so great an increase in PAS resistance.
Evidence has been obtained (Selkon et al., 1960 1)
that strains of tubercle bacilli from Indian and British
1 See article on page 599 of this issue.
patients differ in the pattern of their sensitivity to
PAS. In essence, strains of tubercle bacilli from
Indi n patients, unlike those from British patients,
contain, in general, a proportion of PAS-resistant
organisms, which, although very small, is sufficient
to yield less than 50 colonies on PAS-containing
slopes in many of the tests set up in this Centre’s
laboratory. Consequently, if “ growth ” is defined
 20 or more colonies, minor variations in inoculum
size can cause large changes in the apparent sen-
sitiviti s to PAS of strains from Indian patients.
Thus, a endency to employ a rather larger inoculum
in the present study could well have accounted for
the apparent increase in primary PAS resistance.
Moreover, it has been found that the occurrence of
an pparently resistant strain (according to the above
definitions) does not imply that further tests on the
same strain, or on other strains from the same
patient, will also yield resistant results. It has
therefore been concluded that the definitions of
resistance employed in the earlier study are not
meaningful for the present study and that patients
with primary PAS-resistant strains cannot be iden-
tified by these definitions.
If, on the other hand, growth is defined as 100
or more colonies, then no difference is apparent
between the sensitivities of British and Indian
strains (Selkon et al., 1960 1). In addition, according
to this end-point, there is no increase in primary PAS
resistance between the earlier and the present study.
Two other methods of expressing the results of the
PAS-sensitivity tests in the present study were
theref re investigated. These are: (1) the minimal
i hibitory concentration (MIC) inhibiting the growth
of 20 colonies (1-plus growth); and (2) the MIC
inhibiting the growth of innumerable discrete
coloni s, that is, approximately 100 or more colo-
nies 2 (2-plus growth). (Resistance ratios could not
be used for the 2-plus end-point in place of MICs
because the concentrations of PAS used with the
sta dard sensitive strain, H37Rv, did not always
permit such ratios to be determined.)
For the pretreatment tests in the present study,
the followingdefinitions of resistance, which
2 Whereas the 20-colony end-point was obtained by
counting, the 100-colony end-point was only estimated; its
possible importance was not appreciated until late in the
study.
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screened off a small proportion of the strains as
resistant, were adopted:
Concentration of sodium PAS
(µg/ml)
Definition for 1 -plus MIC :either, more than 16 and more
than 16, on two separate
specimens
or, more than 4 and more
than 64, on two separate
specimens.
Definition for 2-plus MIC: either, more than 2 and more
than 2, on two separate
specimens
or, 2 and more than 4, on
two separate specimens.
For strain H37Rv the 1-plus MIC was on the average
2 µg/ml and the 2-plus MIC 0.5 µg/ml sodium
PAS; so that a l-plus MIC of 16 would on the
average correspond to a resistance ratio of 8 and
a 2-plus MIC of 2 to a resistance ratio of 4.
According to the l-plus MIC definition, 10
(3.0%) of the 338 previously untreated patients
had PAS-resistant organisms (one also had a
streptomycin-resistant strain) and, according to the
2-plus MIC definition,five (1.5%) of the 338
patients had PAS-resistant organisms and two also
had streptomycin-resistant strains. Only two of
the patients had strains which were resistant to
PAS by both definitions. Of the 315 patients in the
main analysis, eight (4 PH, 1 HI-1, 1 HI-2, 2 H)
 had resistant strains according to the 1-plus MIC
 definition (all four PH patients had quiescent
disease at 12 months). Four patients (2 HI-1,
1 HI-2, 1 H) had resistant strains according to the
2-plus MIC definition. In the main analysis, onl  one
patient (HI-1) had a strain which was PAS-resistant
by both definitions. In view of this difficulty in iden-
tifying patients with PAS-resistant strains, it was
decided not to exclude any of the patients from the
main clinical analysis on the grounds of PAS
resistance. The PH series may consequently have
been at a minor disadvantage compared with the
other three series.
The results of PAS-sensitivity tests on strains
obtained during treatment from PH patients were
analysed in terms of both the 1-plus MIC and
2-plus MIC end-points. Considering two definitions
of resistance for each end-point (Tables 16 and 17),
there was very slender evidence of an increase in the
proportions of resistant strains during the later
months. However, the numbers of patients with
positive cultures each month during the last six
months of treatment were very small, ranging only
from 5 to 8. It must be concluded that the value of
the PAS-sensitivity tests on Indian strains remains
uncertain.
STREPTOMYCIN SENSITIVITY
Streptomycin was not included in the standard
chemotherapy and streptomycin-sensitivity tests
were therefore not undertaken during treatment,
unl ss a patient had deteriorated and the chemo-
ther py was changed o include this antibiotic.
Tests were, however, performed on the pretreatment
cultures for all 341 patients, 338 of whom had had
no previous chemotherapy. The great majority of
p tients had two sensitivity tests and a small number
only one. Eleven patients yielded streptomycin-
resistant strains. Interrogation on several occasions
and further inquiries indicated that none of these
had had previous chemotherapy likely to have
been antituberculous. It is therefore probable that
all 11 had been infected with streptomycin-resistant
strains ;this represents a prevalence of primary
streptomycin resistance of 3.3 %.
OTHER BACTERIOLOGICAL FINDINGS
The detailed findings on the pattern of emergence
of isoniazid resistance in the four treatment series,
changes in the catalase activity of the strains, the
virulence in the guinea-pig of the strains isolated both
before and during chemotherapy, and the hydrogen
peroxide susceptibility of the strains will all be
reported elsewhere.
T o t a l C u l t u r e - n e g a t i v e
c u l t u r e s ( n o  s e n s i t i v i t y
e x a m i n e d  * * t e s t  p o s s i b l e )
T o t a l  s e n s i t i v i t y
t e s t  r e s u l t s
a v a i l a b l e
M i n i m a l  i n h i b i t o r y  c o n c e n t r a t i o n T o t a l
“ resistant ” to PAS
( M I C )  i n  µ g / m l
M I C  o f M I C  o f
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8
6 4             
8  µ g / m l
or more      
16 µg
or   
o r  l e s s
( A )
_ _  
0 0 86 * * * 6 7 1 4
118 3 130 96 2 4
214 1 32 2 6 1
2 2 0 0 2 0 1 4 2
16
2
7
3
2
/ m l
m o r e
% of A
3 19 22  5
3 34 26 1 0
2 6 19 5
2
6
8
16
(20)
3
0 8 6
1 ,  2  a n d  3  c o m b i n e d    251
4 , 5 a n d 6 c o m b i n e d 247
7 , 8 a n d 9 c o m b i n e d 2 4 0
1 8 8 
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1 0 ,  1 1  a n d 1 2 c o m -
b i n e d 238 2 1 8 2 1 1 0 ( 5 6 )  
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(2-plus minimal inhibitory concentration end-point)
b u t  n o
s e n s i t i v i t y  t e s t
r e s u l t  a v a i l a b l e
t e s t  r e s u l t s
a v a i l a b l e
8
T o t a l C u l t u r e - n e g a t i v e
c u l t u r e s ( n o  s e n s i t i v i t y
e x a m i n e d  * * t e s t  p o s s i b l e )
0 9 0 0
1, 2 a n d 3  c o m b i n e d 262 122
0 9 0 * * * 6
4 136 8
7 0
7 1
6 2225
232
4, 5 a n d 6 c o m b i n e d 2 5 9
7 , 8 a n d 9 c o m b i n e d 252
2 5 0 2 3 0
*  A l l  p a t i e n t s  h a d  s t r a i n s  s e n s i t i v e  t o  i s o n i a z i d  a n d  t o  P A S  ( a c c o r d i n g  t o  t h e  2 - p l u s  M I C  d e f i n i t i o n - s e e  p a g e  5 6 7 )  o n  a d m i s s i o n  t o  t r e a t m e n t .
* *  P a t i e n t s  w h o  d i e d  a r e  i n c l u d e d  u p  t o  t h e  m o n t h  o f  d e a t h  a n d  p a t i e n t s  w h o  h a d  t h e i r  c h e m o t h e r a p y  c h a n g e d  o n  a c c o u n t  o f  d e t e r i o r a t i o n  or toxicity a r e  i n c l u d e d  u p
t o  t h e  m o n t h  o f  t h e  c h a n g e .
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IX. TOXICITY AND OTHER COMPLICATIONS
TOXICITY
PAS
Three cases of hypersensitivity to PAS were en-
countered among the 90 PH patients, all in the
second month of treatment. Two of these patients
developed rashes ; one was successfully desensitized
in 23 days and the other in rather more than three
months. The third patient developed fever, intense
itching, profuse sweating and albuminuria. These
manifestations reappeared when a test dose of
0.05 g of PAS (sodium) was administered, and the
chemotherapy was therefore changed to strepto-
mycin and isoniazid.A fourth patient developed
jaundice in the second month of treatment; the pre-
scribed regimen was resumed uneventfully after 38
days, and so it was considered that the jaundice had
been due to infectious hepatitis. As in the earlier
study (Tuberculosis Chemotherapy Centre, 1959),
gastro-intestinal side-effects were completely un-
important; it was not necessary to reduce the dosage
of the medicament for any patient on account of
them.
Isoniazid
Twenty patients developed definite peripheral
neuritis attributed to isoniazid-namely, one (1 %)
of 90 PH, 13 (19%) of 70 HI-1 and six (9%) of 68
HI-2 patients. None of the 87 H patients developed
The difference between the HI-1
and HI-2 series does not attain statistical significance.
been reported in detail by Deva-
datta et al. (1960).l Of the 20 cases, 18 were referred
to an independent assessor (either Dr C. E. Klontz or
Dr K. S. Sanjivi) who was unaware of the treatment
series; the diagnosis of peripheral neuritis made by
the Centre’s staff was confirmed in all 18; the other
two cases were diagnosed before the arrangements
for an independent assessment were completed.
The symptomatology was mainly sensory and the
course of the neuritis, when untreated, was charac-
terized by slow progression in all but two of the
patients. All the 20 patients had definite physical
signs of peripheral neuritis. Eight of the patients
developed anaesthesia of the “ stocking ” type (four
of them also having analgesia), eight had loss of
joint sense, 17 loss of vibration sense in the toes
1 See article on page 587 of this issue.
(extending to the ankles in nine cases) and six had
tender calf muscles.Fifteen patients lost their
ankle jerks, and in three the knee jerks were also
lost. Six patients developed muscular weakness. The
o set of the first symptom of peripheral neuritis
occurred between the second month and the tenth
month, occurring rather earlier in the HI-1 patients
than in the HI-2 patients.
Serum isoniazid assays were performed for the
great majority of patients by a microbiological method
(Gangadharam et al., to be published) and it was
found that the patients who developed peripheral
neuritis had a higher mean serum level of the drug
than those who did not develop this complication;
the diff rence in the incidence of peripheral neuritis
mong slow and rapid inactivators attained statistical
signific nce (Devadatta et al., 1960 1).
The 20 cases were managed in several different
ways. The details are reported by Devadatta et al.
(1960).l In only seven (5 HI-1, 2 HI-2) of the
20 patients was the antituberculosis chemotherapy
changed because of the peripheral neuritis (although
one (HI-2) of the seven patients had, in addition, a
radiographic deterioration, confirmed by the inde-
pendent assessor at the same time, and appears in
the tables as a change of chemotherapy due to
deterioration).
Mental disturbance, attributed to isoniazid, oc-
curred in only one (HI-1) patient. This patient, who
also had peripheral neuritis, exhibited signs of
mental disturbance in the third month of treatment.
He developed a premonition of impending death and
was extremely apprehensive. The antituberculosis
chemotherapy was changed, and he was also treated
with pyridoxine; within three months his mental
state had returned to normal.
PREGNANCY
Patients who were known to be pregnant were
not admitted to the study, but two patients (1 PH,
1 H) were subsequently found to have been pregnant
on admission. A further 17 patients (3 PH, 5 HI-1,
5 HI-2, 4 H) became pregnant during the course of
the 12 months; of these, one (H) aborted and three
(1 PH, 1 HI-1, 1 HI-2) were delivered during the
12-month period; the remaining 13 were still preg-
nant at 12 months. The response of pregnant
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patients to antituberculosis chemotherapy will be
the subject of a later report.
LEPROSY
Although patients known to have leprosy were not
admitted to the study it was found in the course of
the 12 months that four patients (1 PH, 1 HI-2, 2 H)
were suffering from leprosy. They received sulfone
therapy as out-patients in the Madras Government
General Hospital. There is evidence that the anti-
tuberculosis effect of sulfone is, at most, small (East
African/British Medical Research Council Sulphone
Investigation, 1960).
HOSPITAL AND SANATORIUM ADMISSIONS
Complicating conditions, whether tuberculous or
non-tuberculous, were usually treated on an out-
patient basis.If the illness was serious, or special
investigation or treatment not available to out-
patients was required, the patients were admitted to
hospital or sanatorium.In all, 12 PH, five HI-1
eight HI-2 and 18 H patients were admitted for
special investigations or treatment (a small number
on two occasions and one for two medical condi-
tions). Of these, two PH, two HI-1, five HI-2 and
12 H patients were admitted because of condition
attributed directly or indirectly to pulmonary tuber-
culosis or to the treatment, including one HI-1
three HI-2 and nine H patients whose chemotherapy
was changed because of radiographic or clinical
deterioration.
The non-tuberculous conditions requiring admis-
sion consisted of five cases of smallpox (3 PH, 2 H),
seven cases of acute or chronic diarrhoea (2 PH,
2 HI-1, 1 HI-2, 2 H), four obstetrical or gynaeco-
logical conditions (2 PH, 1 HI-1, 1 H) and seven
miscellaneous conditions (4 PH, 2 HI-2, 1 H).
The duration of hospitalization for patients with
a tuberculous deterioration was often long and seven
patien s (2 HI-2, 5 H) were in sanatorium for more
than three of the 12 months.
X. SELF-ADMINISTRATION OF THE MEDICINE
The importance of taking the medicine regularly
was emphasized to the patients, both before the start
of treatment and throughout the 12 months. Two
methods were used to check whether the medicine-
taking was regular:
(1) Urine tests were made to detect the presence
of drug in specimens obtained at routine visits of the
patients to the Centre and in specimens obtained at
surprise visits by the staff to the homes. For the PH
patients a ferric chloride test for PAS was used
(Simpson, 1956). For the patients in the HI-1, HI-2
and H series the combined naphthoquinone-
mercuric chloride (combined N-M) test was per-
formed (Short & Case, 1957; Gangadharam et al.,
1958).
(2) Counts were made of the patient’s stock of
tablets or cachets at surprise visits to the homes.
SENSITIVITY OF THE URINE TESTS FOR PAS
AND FOR ISONIAZID
It was important to compare the sensitivity of the
ferric chloride test for PAS and the combined N-M
test for isoniazid, in order to assess the implications
of a negative finding in the urine. In the course of
the routine work of the laboratory, and without the
knowledge of its staff, therefore, two studies were
made on volunteers from the Centre’s national staff
to d termine the period for which the urine would
remain positive after standard doses of each of
four regimens (Table 18).
The first study consisted of two similar investiga-
tions undertaken at different times. In each part 13
volunteers were given a day’s dosage of the PH regi-
me  and of one of the other three regimens (selected
at random), at an interval of approximately 14 days
the order of administration also being determineed at
random. Urine specimens were collected before the
first dose and three, 14 ,18, 26 and 28 hours after
the last dose. The bladder was emptied two hours
before each of these post-treatment specimens was
due. The results of the tests were read as part of
the normal laboratory routine, The tests for PAS
were positive (Table 18) on all except one of the 52
specim ns obtained either at three or at 14 hours
after the last dose of PH, and those for isoniazid
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T A B L E  1 8
R E S U L T S  O F  U R I N E  T E S T S  F O R  P A S  ( I N  S U B J E C T S
G I V E N  I S O N I A Z I D  P L U S  P A S )  A N D  F O R  I S O N I A Z I D
( I N  S U B J E C T S  G I V E N  I S O N I A Z I D  A L O N E )
I N  T W O  S T U D I E S  O N  V O L U N T E E R S
Study   Regimen
26
N u m b e r  o f  v o l u n t e e r s  w i t h
Total              
p o s i t i v e  t e s t  r e s u l t s
v o l u n -
t e e r s
 h o u r s  a f t e r  t a k i n g  t h e  l a s t  d o s e
 0  3  14  18  26  28
 2* 26 25 22  7  5*
8 7 7
7 4 * * 1 * *
7 5 3
P H
H I - 1 1 5 4 * 15 1 4
S e -
c o n d H I - 2 I 1 5 4 15 1 5
H 1 5 3 1 5 1 4
I
*  O n e s p e c i m e n  w a s  n o t  t e s t e d  a t  t h i s  t i m e .
* *  T w o s p e c i m e n s  w e r e  n o t  t e s t e d  a t  t h i s  t i m e .
15 8 8
were positive on all except two of the 49 specimens
obtained at the same intervals after the last dose of
one of the isoniazid-alone regimens. At 18 hours,
22 of the 26 volunteers gave positive results for PAS
and for isoniazid. At 26 and 28 hours, the results for
isoniazid were more frequently positive than those
for PAS, 27 (56%) of the 48 specimens tested for
isoniazid being positive compared with 12 (24%) of
51 tested for PAS, the difference attaining statistical
significance (P<0.01). The combined N-M test
was therefore more sensitive. These results show
that a negative result to either test means that no
drug has been taken for 14 hours (and perhaps for
considerably longer) and, therefore, that the equiva-
lent of a day’s supply of medicine has been missed.
The same conclusions had been drawn from a similar
earlier experiment in which 11 volunteers received
the PH, five the HI-1, three the HI-2 and five the H
regimen. The results have not been included in
Table 18 since, although the readings of the tests
were made in a random order, the laboratory staff
knew that they were reading tests in a special
comparison.
In the second study, which was also made without
the knowledge of the laboratory staff, a more
detailed comparison was undertaken of the persist-
ence of isoniazid in the urine following a day’s
dosage of the HI-1, HI-2 and H regimens. Fifteen
volunteers were given a day’s dosage of each
regimen in a random order, at intervals of approxi-
mately 10 days. The results are set out in the lower
section of Table 18. There were 11 false positive
results in the 44 specimens obtained before any
isoniazid was taken-namely, four in the HI-1,
four in the HI-2 and three in the H subjects; pre-
sumably, therefore,some of the positive results
obtained after the isoniazid was taken may not have
been due to the presence of isoniazid. These false
positive results occurred in a short period when
staff changes were taking place in the laboratory;
both before and after this period, it was very un-
common for tests performed on specimens known
to be free of isoniazid to yield false positive results.
All the specimens gave positive results at three
hours and so did all but two (1 HI-1, 1 H) at 14
hours. At 18 hours, all but two specimens (both H)
were positive. The proportion of positive results
decreased after this time but was higher among the
HI-1 than among the HI-2 or H volunteers. It
may be concluded that for patients on the HI-2
and H regimens, a negative result in a morning
specimen means that no medicine has been taken
that morning or on the previous evening. For
patients on the HI-1 regimen it indicates that no
medicine has been taken on that morning and
probably at no time during the previous day.
REGULARITY OF SELF-ADMINISTRATION OF THE
MEDICINES
The results of tests performed on specimens of
urine obtained from the patients at the routine
weekly visits to the Centre are set out in Table 19.
Since these specimens were obtained at every visit
(except in the case of female patients who were
menstruating), they permit a valid comparison of
the acceptability of the four regimens. The average
nu ber of tests per patient per month was 4.0
for each of the four treatment series, and was a
li tl higher in each series for the males than for the
females. The proportion of negative test results
ranged from 4.8% to 6.6% (Table 19), and was
slightly higher for the females in each treatment
eries than for the males. The proportion of negative
results was thus low in all four treatment series.
Even allowing for the fact that a negative result
generally means that at least two doses of the
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m a l e s f e m a l e s m a l e s    f e m a l e s
N u m b e r  o f  p a t i e n t s
w i t h t e s t  r e s u l t s * 5 6 3 0 3 5 2 9
T o t a l  n u m b e r  o f
t e s t r e s u l t s 2 7 2 2 1370 1714 1308
Average number of   
t e s t  r e s u l t s  p e r
p a t i e n t  p e r  m o n t h    4.1                3.7  4.1          3.9
N u m b e r  o f  t e s t
r e s u l t s  w h i c h  w e r e
n e g a t i v e
P e r c e n t a g e  o f  t e s t
r e s u l t s  w h i c h  w e r e  
n e g a t i v e
118 78 73 105
4.3                        5.7 4.3 8.0
4.8 5.9
H I - 2
i
H
m a l e s f e m a l e s m a l e s f e m a l e s
4 8 18 53 3 1
2 2 0 9 719 2499 1194
4.1 3.9 4.0 3.9
1 1 1     161  814 6
5.0            6.4              6.4              6.8
5.4 6 . 6
*  E x c l u d i n g  t w o  m a l e  ( 1  H I - 2 ,  1  H )  a n d  t h r e e  f e m a l e  ( 2  P H ,  1  H I - 1 )  p a t i e n t s  w h o  d i e d  o f  n o n - t u b e r c u l o u s  c o n d i t i o n s ,  f o u r  m a l e
( 1  P H ,  3  H I - 1 )  a n d  f o u r  f e m a l e  ( 1  P H ,  2  H I - 1 ,  1  H I - 2 )  p a t i e n t s  w h o  h a d  t h e i r  c h e m o t h e r a p y  c h a n g e d  on a c c o u n t  o f  t o x i c i t y  a n d  o n e
m a l e  ( H )  a n d  o n e  f e m a l e  ( H )  p a t i e n t  w h o  d i e d  o f  t u b e r c u l o s i s  w i t h i n  o n e  m o n t h  o f  t h e  s t a r t  o f  c h e m o t h e r a p y . P a t i e n t s  w h o  d i e d
o f  t u b e r c u l o s i s  h a v e  b e e n  i n c l u d e d  u p  t o  t h e  m o n t h  o f  d e a t h  a n d  p a t i e n t s  w h o  h a d  t h e i r  c h e m o t h e r a p y  c h a n g e d  o n  a c c o u n t  o f
d e t e r i o r a t i o n  h a v e  b e e n  i n c l u d e d  u p  t o  t h e  m o n t h  o f  t h e  c h a n g e .
medicine have been missed, the findings suggest
that the medicine was being taken with considerable
regularity throughout the 12 months. However,
it must be emphasized that this conclusion is based
on specimens obtained at routine visits to the
Centre, when patients knew that tests would be
made. The degree of irregularity may therefore have
been underestimated.
The similarity of the findings in the PH series
(4.8 % of tests negative) and the H series (6.6%)
is of particular interest.The PM patients had to
take large white cachets each weighing more than
1.5 g and containing 1.25 g of PAS and 25 mg of
isoniazid, while the H patients took smaller pink
tablets each weighing 0.5 g and containing 25 mg
of isoniazid, but no PAS. The number of cachets or
tablets to be taken daily was the same for the two
regimens and, in both, the medicine was given in
two doses. There is no evidence that the PAS-
containing cachets were any less acceptable than the
isoniazid tablets, and they may even have been more
acceptable. The HI-1 and HI-2 regimens were of
similar acceptability; this is also of special interest
since the same number of identical tablets was
prescribed daily in each regimen, but as a single
morning dose for the HI-1 patients and as a morning
and n vening dose for the HI-2 patients.
Table 20 shows the distribution of the patients
n the four treatment series, according to the per-
centage of negative results at the routine visits.
Twenty-seven (31%) of the PH patients, 18 (28 %)
of t e HI-1, 25 (38 %) of the HI-2 and 22 (26 %) of
the H patients never produced a negative result.
A further 38 % of the PH, 25 % of the HI-1, 30 % of
the HI-2 and 27% of the H patients produced
negative results in less than 5 % of tests.In contrast,
there were 17 patients (4 PH, 4 HI-1, 4 HI-2, 5 H)
with negative results in 20% or more of the tests.
Of these, two PH patients produced negative results
in 48 % and 50 % of their tests, respectively, two HI-2
patients in 38 % and 49%, respectively, and one H
patient in 84% of his tests. In summary, the distri-
butions for the four treatment series were similar.
RESPONSE TO TREATMENT IN RELATION TO THE
REGULARITY OF MEDICINE-TAKING
Table 20 also relates the percentage of urine tests
with negative results to the frequency of unfavourable
re ponse to treatment during the 12 months, defined
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as death from tuberculosis; bacteriologically active
disease at 12 months, including deterioration leading
to change of chemotherapy; or bacteriologically
relapsed disease at 12 months.
In the PH series there was no suggestion of an
association between irregularity in medicine-taking
and an unfavourable response; two (7%) of the
27 patients whose urine tests were always positive
had an unfavourable response, compared with six
(10 %) of 59 patients who produced negative results
on one or more occasions.I  the HI-1 series,
however, two (11%) of 18 patients who produced
no negative results showed an unfavourable response,
compared with 15 (33 %) of 46 whose urine specimens
yielded one or more negative results ; this difference
borders on statistical significance (P = 0.07). The
likelihood of a genuine association in this series is
increased by an analysis (not tabulated here) which
showed that the patients whose urine test results
were all positive were at a slight disadvantage in
pretreatment clinical condition, compared with
those who showed irregularities in medicine-taking.
In the HI-2 and H series, the percentages of
patients showing unfavourable responses were high,
even among those whose results were all positive.
Thus, unfavourable responses occurred frequently
with these regimens, even when they were being
taken regularly.
FINDINGS AT SURPRISE VISITS TO THE PATIENT’S
HOME
Information on the regularity of self-administra-
tion of the drugs from surprise visits to the home,
whether obtained from urine testing or from counts
of the stock of medicine, is valuable as a means of
checking the co-operation of the individual patient.
In the present study the information is much less
suitable for analysis than that obtained from the
routine urine specimens at the Centre. In the first
place, the findings at surprise visits are subject to
bias, since data were more likely to be obtained from
ill patients resting at home than from patients who
had returned to work. Moreover, on finding a
negative urine result or an excessive stock of medi-
cine, the doctors often requested the health visitors
to pay more frequent surprise visits. Finally, less
information was available since surprise visits to the
home were paid much less frequently than the routine
visits by the patient to the Centre. Because of these
shortcomings no analyses of the data obtained at
surprise visits are presented here.
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XI. VARIOUS SOCIAL FACTORS
REST AND ACTIVITY
The general policy which was adopted was to
persuade the patients to rest as much as possible in
the early weeks of treatment. As their general
condition improved they were allowed to increase
their activity, and many were in their normal full-
time occupations at the end of the year. It was
difficult to estimate accurately the degree of activity,
since many patients, unless actually feeling ill, would
sit or potter around at home much of the day and
often go for walks.The great majority of the
patients, in addition, attended the Centre weekly
throughout the 12 months for a supply of medicine
and usually, because they could not afford the
fares, had to travel on foot, some a distance of up
to 5 miles (8 km) each way. Table 21 sets out the
assessment of the activity at six and 12 months for
the males and females separately. Considering the
males first, at six months, 41 % of the PH, 46%
of the HI-1, 44 % of the HI-2 and 28 % of the H
patients were on part-time or full-time activity, the
majority being on part-time. By 12 months the
proportions had increased to 91%, 86 %, 83 % and
72 %, respectively.Considering the females, at six
months, 58 % of the PH, 43 % of the HI-1, 39 % of
the HI-2 and 56% of the H series had resumed at
least part-time activity. At 12 months the propor-
tions were 97 %, 79 %, 61% and 59 %, respectively.
It may be concluded that the majority of patients,
both male and female, had returned to at least
part-time activity by the end of the period, and that
many had done so by six months.
INCOME OF THE FAMILIES BEFORE TREATMENT
The total family income at the start of treatment
was assessed by adding the average monthly income
of the patient, in the six months immediately prior
to admission to treatment, to the monthly income
from any source of all the other family members,
at the time of admission of the patient. Although
the patients and their families were questioned
carefully during treatment of the patient, as well as
at the start, it will be appreciated that it remains
uncertain whether all the families revealed all their
sources of income.
The great majority of the family incomes-namely,
80% of those for the PH series, 77 % for the HI-1
series, 78% for the HI-2 series, and 83 % for the
H series–lay between Rs 40.00 and Rs 150.00 per
month ;1 a number of families had lower, and a few
had higher, total incomes. These data have not been
tabulated here, because a knowledge of the total
family income is of limited value unless it is related
to the size and to the age- and sex-composition of
the family. With this in view, therefore, each family
has been expressed, as in the 1959 report, in terms
of standard units; an adult male was equivalent to
1 standard unit, an adult female was taken as 0.8,
and a child under the age of 15 years as 0.6 standard
unit (India, Ministry of Commerce, 1949). The
total income of each family was then expressed as
the income per standard unit; the findings are
presented in Table 22.
Considering the families of male patients first,
37 % of 57 in the PH series, 24 % of 38 in the HI-1
series, 3 1% of 49 in the HI-2 series and 25 % of 55
in the H series had an income per standard unit of
less than Rs 20.00 per month ; only two families of
PH patients, three of HI-1 patients, six of HI-2
patients and four of H patients had a monthly
income of Rs 50.00 or more per unit. Considering
the families of female patients, 67 % of 33 in the PH
series, 44% of 32 in the HI-1 series, 53 % of 19 in
the HI-2 series and 62% of 32 in the H series had
an income per standard unit of less than Rs 20.00
per month; only three families (all of HI-1 patients)
had a monthly income of Rs 50.00 or more per
unit. The reported family incomes were thus rather 
lower, in terms of standard units, for female than 
for male patients.
In these families most of the income is spent on 
food. Chaudhuri (1959), referring to the current
cost of living in India, stated that “ at present price
levels, a balanced diet for 1 adult costs at least
Rs 1.50 a day (Rs 45.00 a month); and the minimum
total requirement, including food and clothing, is
about Rs 60-70 per month ”.
FINANCIAL ASSISTANCE TO THE FAMILY
As explained in an earlier report (Tuberculosis
Chemotherapy Centre, 1959), a fund was available
to provide limited financial assistance to the families
of especially needy patients.An analysis (not
tabulated here) was undertaken of the financial
1 Rs 4.80 = US$ 1.00.
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P H Y S I C A L  A C T I V I T Y  O F  T H E  P A T I E N T S  A T  6  A N D  A T  1 2  M O N T H S
- - -
F e m a l e s  * *M a l e s  *
1 2  m o n t h s1 2  m o n t h s I
. I -
I
P h y s i c a l   6  m o n t h s
activity                              
o f  p a t i e n t  
P H  H I - 1 H I - 2   
6  m o n t h s
P H H I - l HI-2 HP H H I - 1 H I - 2 H
No. % No. % N o . % No. %N o .  %
P H H I - 1 H I - 2 H
No. % No. % No. % No. %
I ’
1 2 34 6 1 18 5 1 21 44 25 4 6 2 6 1 3 2 ( 11 ) * * * 5 1 6F u l l - t i m e 3 5 3 8 2 4
No. %  No. % No. %  No. %
2 2 73 1 2 47 1 1 (67) 1 1 34
12 3 4 14 2 617 3 0 5 (28) 13 4 1 7 23 1 1 38 9 (0) 8 25
10 (56)  7 2 2 0 0 2 7 0 (0) 0 0
P a r t - t i m e 20 3 6 14 3 8 19 4 0 14 2 6
S l i g h t 35 6 5
R e s t i n g 0 0 0 0 0 (0)  1 30 ( 0 ) 1 33 6 3 6
 C h a n g e  o fc h e m o t h e r -
apy due to              0     0        0      0    
d e t e r i o r a -
t i o n
1 3 4 14 7 (39) 10 311 (6) 4 12
0 (0) 2 6
0 0
0 0
3 1 100
0 0 0 0 0 (0) 2 6
I
0 0 1 2 1 2
i  I
35 9 9 54 100
Tubercu-  1 2
l o u s  d e a t h
3 0 99 2 9 100 1 8 100 3 2 99
- -
T o t a l
p a t i e n t s
56 100 1 8  1 0 1 32 10056 100 30 9 94 8  100
*  E x c l u d i n g  t h r o u g h o u t  t w o  p a t i e n t s  ( 1  H I - 2 ,  1  H )  w h o  d i e d  o f  n o n - t u b e r c u l o u s  c o n d i t i o n s  a n d  t w o  p a t i e n t s  ( 1  P H ,  1 H I - 1 )  w h o  h a d  t h e i r  c h e m o t h e r a p y  c h a n g e d  o n
a c c o u n t  o f  t o x i c i t y  i n  t h e  f i r s t  s i x  m o n t h s ;  e x c l u d i n g  a l s o ,  a t  1 2  m o n t h s  o n l y ,  t w o  p a t i e n t s  ( b o t h  H I - l )  w h o  h a d  t h e i r  c h e m o t h e r a p y  c h a n g e d  o n  a c c o u n t  o f  t o x i c i t y  i n  t h e
s e c o n d  s i x  m o n t h s .
* *  E x c l u d i n g  t h r o u g h o u t  t w o  p a t i e n t s  ( 1  P H ,  1  H I - 1 )  w h o  d i e d  o f  n o n - t u b e r c u l o u s  c o n d i t i o n s  a n d  t h r e e  p a t i e n t s  ( 1  P H ,  1  H I - 1 ,  1  H I - 2 )  w h o  h a d  t h e i r  c h e m o t h e r a p y  c h a n g e d
o n  a c c o u n t  o f  t o x i c i t y  i n  t h e  f i r s t  s i x  m o n t h s ;  e x c l u d i n g  a l s o ,  a t  1 2  m o n t h s  o n l y ,  o n e  p a t i e n t  ( P H )  w h o  d i e d  o f  a  n o n - t u b e r c u l o u s  c o n d i t i o n  a n d  o n e  p a t i e n t  ( H I - l )  w h o  h a d
h e r  c h e m o t h e r a p y  c h a n g e d  o n  a c c o u n t  o f  t o x i c i t y  i n  t h e  s e c o n d  s i x  m o n t h s .
* * *  P e r c e n t a g e s  b a s e d  o n  f e w e r  t h a n  2 5  o b s e r v a t i o n s  a r e  e n c l o s e d  i n  p a r e n t h e s e s ,  a s  a n  i n d i c a t i o n  o f  t h e  s m a l l  t o t a l s .
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T A B L E  2 2
T O T A L  F A M I L Y  I N C O M E  B E F O R E  T H E  S T A R T  O F  T R E A T M E N T ,  E X P R E S S E D  I N  T E R M S  O F  S T A N D A R D  U N I T S *
0 - 2 4 2 5 1 2 4 7  3 9 2 6   0   ( 0 ) * * *  4 12
1 0  - 19 3 3 7 18 14 29 1 0 18  1 9 58 1 2 38 10 (53) 16 50
2 0  - 25 4 4 1 6 42 16 33 2 3 42  6 18 1 0 31 5 (26) 1 0 31
3 0  - 7 12 7 18 6 12 1 2 22  4 12  5 16 2 (11) 2 6
4 0  - 2 4 3 8      6     12       2 4 1 3 0 0 2   (11)          0 0
5 0  - 0 0 3 8 5 10 0 0 0 0 2 6 0 ( 0 ) 0 0
6 0  o r  m o r e 2 4 0 0 1 0 ( 0 ) 0 0
T o t a l  f a m i l i e s 57 1 0 1 3 3 99 49 100 5 5 100 
i 3 3 100 3 2 100   19  101 3 2 99
_ _ _ _  
* An adult male (15 years or over) was counted as 1 standard unit, an adult female (15 years or over) as 0.8 of a standard unit
a n d  a  c h i l d  b e l o w  1 5  a s  0 . 6  o f  a  s t a n d a r d  u n i t .
** Rs 4.80 = US$ 1.00.
* * *  P e r c e n t a g e s  b a s e d  o n  f e w e r  t h a n  2 5  o b s e r v a t i o n s  a r e  e n c l o s e d  i n  p a r e n t h e s e s ,  a s  a n  i n d i c a t i o n  o f  t h e  s m a l l  t o t a l s .
Families of male patients in study Families of female patients in study
Income
per standard
unit (in rupees**
per month)
assistance provided by the Centre. In the case off milies of female patients, 61 % of 33 PH families,
patients who died or had their treatment changed,31% of 32 HI-1, 58% of 19 HI-2 and 61 % of 31 H
only the assistance given up to the time of death orfamilies received financial assistance. The average
change of chemotherapy has been included. Con-monthly payment for the families receiving financial
sidering the families of male patients first, 75% ofassistance was Rs 4.32, Rs 4.36, Rs 3.62 and Rs 3.73,
57 PH families, 63 % of 38 HI-1, 73 % of 49 HI-2 andrespectively. The proportions of these families
80% of 54 H families received financial assistance.which received, on the average, less than Rs 5.00 a
The average monthly payment for the familiesonth were 55 %, 50 %, 55 % and 68 %, respectively
receiving assistance was Rs 7.69, Rs 5.70, Rs 7.72in the four series. Only one family (PH) received
and Rs 8.50, respectively. Of these, 35 % of themore than Rs 15.00 a month (Rs 16.50). It may be
families of patients in the PH series, 62 % in the HI-1,concluded that the financial assistance was kept to
25 % in the HI-2 and 16 % in the H series receiveda low level and that the families of male patients, as
assistance of less than Rs 5.00 a month, on thein the earlier study (Tuberculosis Chemotherapy
average.Only one family (H) received more thanCentre, 1959), received more financial assistance
Rs 20.00 a month (Rs 28.21). Considering thethan those of female patients.
XII. PATIENTS NOT INCLUDED IN THE MAIN ANALYSIS
This section reports on the total of 26 patients
(6 PH, 5 HI-1, 7 HI-2, 8 H) who were separated from
the main analysis, 22 because they were excreting
isoniazid-resistant organisms at the start of treat-
ment and four for other reasons, given below.
PATIENTS WITH ISONIAZID-RESISTANT ORGANISMS
AT THE START OF TREATMENT
Twenty-two patients had isoniazid-resistant organ-
isms when treatment began. All the patients were
int rrogated on several occasions during the course
of treatment, as their relationship of trust with the
Centre’s staff became more and more firmly estab-
lish d, to discover whether they had had previous
chemotherapy and were concealing the fact. Two
admitted that they had had previous chemotherapy
which was believed to have included isoniazid. The
duration of chemotherapy for each of these two
patients was probably one month. Of the remaining
20 patients, 19 had no history of previous chemo-
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therapy and the twentieth had had a week of strepto-
mycin plus isoniazid. It is considered that these 20
patients (5.9% of the 337 patients who had had no
previous chemotherapy or, in 12 cases, up to two
weeks’ chemotherapy and for whom pretreatment
isoniazid-sensitivity test results were available) had
been infected with isoniazid-resistant organisms, that
is, had primary isoniazid resistance. Every effort
was made to discover whether any of the 341 patients
had had previous antituberculosis chemotherapy; for
example, dispensary cards from other hospitals and
prescriptions from private doctors were scrutinized.
In addition,relatives and, where appropriate,
friends, were approached.
Of the two patients who had had previous chemo-
therapy, one (HI-1) deteriorated radiographically
and the chemotherapy was changed; the other
(HI-2) had active disease at 12 months.
Detailed findings for the 20 patients with primary
isoniazid resistance will be reported elsewhere, but
the clinical findings are summarized here. Of the 20
patients, six were in the PH series, two in the HI-1,
six in the HI-2 and six in the H series. The results
of two pretreatment sensitivity tests were available
for all; five PH, one HI-1 all six HI-2 and five
H patients had resistant results to both tests, and
the remaining three patients (PH, HI-1, H) had one
resistant and one sensitive result.
Of the six PH patients, one had bacteriologically
quiescent disease at one year, four who had con-
tinued on the regimen had bacteriologically active
disease and one had deteriorated radiographically
therapy had been changed. Both HI-1
active disease at one year. Of the
two had quiescent and four active
the six H patients responded un-
favourably; one, who was admitted to sanatorium
and received streptomycin and PAS in addition to
the isoniazid for 18 days, died of tuberculosis in
the third month; two deteriorated radiographically
and their chemotherapy was changed, two who had
conti ued on the regimen had bacteriologically
active disease at 12 months and one had relapsed
bact riologically.
Five of the six PH patients with primary isoniazid
resist nce had an unfavourable bacteriological
r sponse, whereas only eight of 86 PH patients with
ison azid-sensitive organisms in the main analysis
had responded unfavourably; this difference is
statistically highly significant (P<0.001). Of the
14 patients with primary isoniazid resistance in the
three isoniazid-alone regimens combined, 12 had an
unfavourable response compared with 93 of 216 with
sensitive organisms; this difference also is statistically
ghl  significant (P<0.01). It may be concluded
tha  the patients with primary isoniazid resistance
fared badly bacteriologically, whether they were
t eated with isoniazid alone or with isoniazid plus
PAS.
PATIENTS EXCLUDED FOR OTHER REASONS
Four patients were separated from the main
analysis for reasons other than isoniazid resistance
at the start of treatment. One HI-1 patient ab-
scond d in the second month; at the end of the year
he still had bacteriologically active disease. Another
(HI-1) was, in error, advised by a staff member to
take his medicine in two doses a day instead of one
and did so for two months; he had disease of
bacteriologically doubtful status at one year. One H
patient, who had a carcinoma of the bronchus, died
from this cause in the eleventh month of treatment.
F nally, an H patient with isoniazid-sensitive
organisms, who had had two months of previous
chemotherapy, believed to be isoniazid plus strepto-
mycin, had disease of bacteriologically doubtful
status at one year.
XIII. DISCUSSION
Since the introduction of isoniazid there has been“ 1. that a large body of medical opinion has con-
much controversy concerning the use of this drugsidered that, because of simplicity of use and its low cost,
by itself in the treatment of pulmonary tuberculosis.isoniazid, administered by itself, is at present the best
In a recent report on a clinical study of isoniazidavailable chemotherapy for mass treatment of patients
alone compared with combined oral chemotherapy,out of hospital in underdeveloped countries;
carried out in East African patients in hospital (East
African/British Medical Research Council Isoniazid
2. that this treatment is already being given either
from official or from unofficial sources in many areas,
Investigation,1960), the reasons for undertakingand that it is urgently necessary to determine whether
that study were summarized as follows: this is justified;
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3. that remarkable clinical and radiographic improve-
ment is known to result from treatment with isoniazid
alone; and
4. that even if substantial proportions of patients
remain sputum positive with isoniazid-resistant organisms
following treatment with isoniazid alone, the importance
of these organisms to the patients and to their contacts
has not been fully elucidated, and is still the subject of
controversy.”
It was these reasons which also led to the study
which is reported here and to a concomitant investi-
gation of the incidence of tuberculosis in family
contacts which will be reported later. The study
under discussion was designed to evaluate the
relative merits of three different dosages of isoniazid
alone, in comparison with a standard regimen of
isoniazid plus PAS, prescribed as two doses daily
(PH). The three isoniazid regimens were isoniazid,
in the same amount as in the PH regimen (a daily
dosage, on the average, of 4.5 mg/kg body-weight),
given in two doses a day (H), and isoniazid in a
daily dosage, on the average, of 8.7 mg/kg, given
either as one dose a day (HI-1) or as two doses a day
(HI-2). The comparison of the PH and H regimens
permitted an assessment of the value of PAS in the
PH combination. The other two regimens con-
tained the largest dose of isoniazid which it seemed
likely could be given (in the absence of pyridoxine
supplements) without an unduly high proportion of
the malnourished patients under study developing
peripheral neuritis. This higher dosage was studied
because of the possibility that it would have greater
efficacy than the lower dosage, and the two rhythms
of administration were included because of the
possibility that there might be differences between
them either in acceptability for self-administration
or in therapeutic effectiveness. The 341 patients were
drawn from a poverty-stricken section of a large
urban community in South India and were treated
under ambulatory conditions in their own homes for
a year, unless admission to sanatorium became
necessary.
ASSESSMENTS OF THE RESULTS
The findings in the four treatment series for the
year may be assessed in four ways-namely, in terms
of two criteria of unfavourable response of the tuber-
culous disease, in terms of toxicity, and in terms of
unfavourable response and toxicity.
1. Unfavourable response of the disease may be
defined first as bacteriologically relapsed or bacterio-
logically active disease at the end of the year (see
Table 12), including definite radiographic or serious
clinical deterioration necessitating a change of
chemotherapy during the year, or death from tuber-
culosis during the year. Such a response occurred in
9 % of the PH, in 27 % of the HI-1, in 42 % of the
HI-2 and in 56 % of the H patients; the PH treatment
thus showed a clear advantage over the other three
regimens. Further, there was evidence that the
apparent slight superiority of the HI-2 over the H
treatment was associated with a lower average
virulence in the guinea-pig of the pretreatment
(isoniazid-sensitive) strains of organisms in the HI-2
patients. When statistical standardization was
undertaken for pretreatment virulence, the relatively
small difference between the HI-2 and H treatments
in terms of unfavourable response virtually dis-
appeared. These two treatments thus proved closely
similar in their effects, and were equally unsatis-
factory.
2. It is well established that many iso iazid-
resistant strains of tubercle bacilli have a lowered
virulence in the guinea-pig (Barnett et al., 1953;
Middlebrook & Cohn, 1953; Peizer et al., 1953;
Morse et al., 1954). A number of authorities believe
that this observation applies in man also and, as a
consequence,that the emergence of isoniazid-
resistant strains during treatment, associated with
persisting bacteriological positivity, is not neces-
sarily a serious event, either for the patient (Deuschle
et al., 1954; Middlebrook & Dressler, 1954; Oestrei-
cher et al., 1955) or for his contacts. Unfavourable
response may therefore be defined in a second way,
by regarding sputum positivity as relatively un-
important and considering only definite radiographic
or serious clinical deterioration leading to change
of chemotherapy during the year, or tuberculous
death, as an unfavourable response of the disease
to treatment. When viewed in this way, 23 % of the
HI-2 and 21% of the H patients showed an un
favourable response; these treatments thus remained
unsatisfactory.The PH and HI-1 treatments were
much more satisfactory, and on this criterion the
difference between them was relatively small, for
2% of the PH patients and 8 % of the HI-1 patient
had an unfavourable response.
It will be possible, in due course, to assess the
progress in a second year of treatment of those
patients who had bacteriologically active or bacterio-
logically relapsed disease at the end of the first year,
but had not had their chemotherapy changed
owing to radiographic or clinical deterioration;
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these patients amounted to 19 % of the total on the
HI-1 regimen, compared with 7 % of those on the
PH regimen, and nearly all of them continued on
the originally prescribed regimen in the second
year. If, in this period, these patients deteriorate
radiographically or clinically, then the HI-1 treat-
ment will compare less favourably with the PH
treatment than it does at the end of the first year.
If, on the other hand, the organisms disappear
from the sputum and most of these patients attain
bacteriological quiescence, the HI-1 and PH treat-
ments will approach one another in effectiveness
with, at most, a relatively minor advantage to the
PH treatment.
3. The treatments may be compared in terms of
major toxic manifestations.The occurrence of
hypersensitivity and toxic manifestations to PAS
is well known (Jones, 1954) and three (3%) of the
PH patients had such complications. One further
PH patient developed peripheral neuritis, an un-
usual complication when isoniazid is given in low
dosage (Great Britain, Medical Research Council,
1952b, 1953a, 1953b, 1955; Mount et al., 1953;
Tuberculosis Chemotherapy Centre, 1959), although
Money (1959), in a malnourished community in
East Africa, encountered an incidence of 20% when
giving a dosage of 4-6 mg/kg daily. It is an increas-
ingly frequent occurrence as the dosage is increased
(United States, Public Health Service, 1954; Biehl &
Nimitz, 1954). There were no cases of peripheral
neuritis or other toxic manifestations among the
H patients, but 19 % of the HI-1 and 9 % of
the HI-2 patients developed peripheral neuritis in
the course of the year; the difference between these
two percentages does not attain statistical signifi-
cance. The occurrence of peripheral neuritis must
be considered a major disadvantage of both these
treatments, and especially of the HI-1 regimen.
4. The treatments may be compared by taking
into account both unsatisfactory response of the
tuberculous disease and the toxic manifestations.
When assessed in this way, the PH regimen still
remains the most satisfactory, since there were few
unfavourable responses (by either definition) and
few cases of toxicity.The HI-1 regimen was rela-
tively unsatisfactory by the first definition of un-
favourable response, and more satisfactory by the
second, but had a high level of toxicity. The HI-2
and H regimens were the least satisfactory by both
definitions of unfavourable response, and toxicity
was an additional disadvantage in the HI-2 regimen.
In summary, only the PH regimen emerged as a
good form of chemotherapy for domiciliary treat-
ment. The findings with this regimen in the present
study are rather better than those reported in
domiciliary patients in an earlier study in Madras
(Tuberculosis Chemotherapy Centre, 1959). In the
arlier study, 83 % of 81 patients had bacteriologi-
call  quiescent disease (or disease of bacteriologically
doubtful status) at one year, compared with 91 %
of 86 patients in the present study.
COMPARISON WITH OTHER STUDIES OF ISONIAZID
ALONE
In the controlled investigation of patients in
hospital in East Africa (East African/British Medical
Research Council Isoniazid Investigation, 1960)
referred to above, two of the regimens were identica1
with the PH and H regimens of the present study.
In East Africa, as in India, the PH regimen was
found to be satisfactory, whereas the H regimen was
much less effective. A third regimen in the East
African investigation was a very large dosage of
isoniazid (about 20 mg/kg body-weight daily, given
in two doses). It proved only slightly more effective
than the H regimen in East Africa; this is in clear
contrast to the findings in India, where the HI-1
regimen (about 8.7 mg/kg daily in one dose) was
definitely more effective than the H regimen. This
may be related to possible differences in the severity
of the disease in the two studies. However, the
patients on the high dosage of isoniazid in East
Africa also received a large dose of pyridoxine to
prevent isoniazid toxicity, and there is experimental
evidence (McCune et al., 1957) that pyridoxine may
interfere with the antituberculous activity of the
isoniazid.It is thus uncertain precisely what effective
dosage of isoniazid these patients actually received.
Phillips (1959) reported on a controlled study of
minimal or moderately advanced non-cavitated
disease in hospitals in the USA treated either with
isoniazid alone (300 mg daily, given in three doses)
or with the same dosage of isoniazid, plus PAS. At
ight months the results of the two treatments were
similar, so that isoniazid alone was as effective as
the combination isoniazid plus PAS for the treat-
ment of non-cavitated lesions in North America.
It is of particular interest to see whether this con-
clusion is confirmed in the Madras patients with
the less extensive lesions. The HI-2 and H treatments
were found to be unsatisfactory even in patients
with o cavitation or cavitation of slight extent,
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with radiographic lesions whose total extent was
limited or slight, or with small numbers of tubercle
bacilli in the sputum on smear examination; in
contrast, the PH treatment was very satisfactory
under these conditions; the HI-1 regimen was less
effective than the PH regimen but more effective
than the HI-2 or the H regimen. The therapeutic
equality of isoniazid alone and isoniazid plus PAS
reported by Phillips (1959) in hospital patients in
the USA therefore does not appear to extend to
even the lesser grades of the more serious disease
under domiciliary treatment in India in the present
investigation.
PERIPHERAL NEURITIS
The clinical aspects of the peripheral neuritis
have been reported in full elsewhere (Devadatta et
al., 1960 1), but merit brief consideration here. The
onset of the complication was usually insidious, the
progression slow and the symptoms and signs mainly
sensory. Muscular weakness was less common and,
when it occurred, mild. In only two of the 20
patients did the peripheral neuritis present in a more
acute fashion. There was, thus, usually adequate
warning that it was developing, especially as the
patients were seen weekly. Even with less frequent
observation nearly all the lesions would have been
detected at a relatively early stage.
The usual way of treating peripheral neuritis due
to isoniazid is to change to a combination not
containing that drug, and to give large doses of
pyridoxine as a specific treatment. Since this vitamin
is expensive it may not be practical to treat peripheral
neuritis in this way in under-developed countries.
If convenient and cheap ways could be found to
prevent peripheral neuritis, or to treat it effectively
in the early stages, then it might be possible to give
even larger single doses of isoniazid alone than
those in the HI-1 regimen, with the possibility of
greater effectiveness in the therapy of tuberculosis.
In this connexion, Turner (personal communication,
1958) has reported that oral administration of a
vitamin B complex preparation which did not
contain pyridoxine was effective treatment for
peripheral neuritis even if the isoniazid was con-
tinued. Money (1959) has reported similar findings
with yeast tablets in 13 of 16 patients. Further
studies on the prevention and treatment of peripheral
neuritis due to isoniazid in Indian patients are in
progress.
1 See article on page 587 of this issue.
SELF-ADMINISTRATION OF THE CHEMOTHERAPY
The problem of keeping the co-operation of
tuberculous patients is well recognized in the long-
term self-administration of oral chemotherapy
with medicaments that contain PAS (Simpson, 1956;
Dixon et al., 1957; Rigby, 1958; Wynn-Williams &
Arris, 1958) and lack of co-operation is usually
attributed specifically to the non-acceptability of
that drug. However, no comparison has hitherto
been reported of the relative acceptability of medica-
ments which do and do not contain PAS. It is not
sufficiently widely appreciated that there is a general
difficulty in the long-term self-administration of
medicaments, and that this also applies to tuber-
culous patients.The difficulty has already been
shown to apply to the self-administration of a
single tablet of isoniazid a day and of a single tablet
a d y of a placebo, calcium gluconate (Velu et al.,
1960 2). As part of the present study the acceptability
for self-administration of large white cachets con-
taining both PAS and isoniazid has now been com-
pared with that for very much smaller tablets
containing isoniazid alone, the same total number of
c chets as of tablets being prescribed daily in two
doses. Examinations of the urine for PAS in the PH
patients, using the ferric chloride test (Simpson,
1956), and for isoniazid in the H patients, using the
combi ed naphthoquinone-mercuric chloride test
(Gangadharam et al.,1958), the latter test having
been shown to be rather more sensitive. indicated
that he two medicaments were of the same order of
acceptability.There was, thus, no evidence either
that the PAS content or the greater bulk of the
cac ts produced any greater irregularity in self-
administration than was encountered with the
smaller isoniazid tablets; the factors which may
a count for the difficulty of self-administration of
medicaments have been discussed elsewhere (Fox,
1958). Considering the HI-1 and HI-2 regimens,
which differed only in that the daily dosage of the
former was prescribed as a single dose in the morning
and of the latter as a morning and an evening
dose, there was no evidence that either regimen was
more acceptable than the other. Indeed, all four
regimens in the present study appear to have been
of the same order of acceptability. As in previous
studie  (Wynn-Williams & Arris, 1958; Tuberculosis
Chemotherapy Centre, 1959; Luntz & Austin, 1960;
Velu et al., 1960 2), there was evidence of greater
ir gularity in drug-taking among the females than
among the males.
2 See article on page 511 of this issue.
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There was some evidence that the irregularity in
self-administration in the HI-1 series was associated
with unfavourable response according to the first
of the two definitions referred to above; 11% of
18 patients whose urine tests were always positive,
compared with 33 % of 46 whose urine tests yielded
one or more negative results, had an unfavourable
response. (This difference just fails to attain statis-
tical significance.) It follows that the HI-1 regimen
might be less effective in a mass campaign, where
considerably more irregularity might be encountered,
than in the carefully supervised patients in this
study. Such a delicate balance was not found with
the PH regimen and, as in an earlier study (Tuber-
culosis Chemotherapy Centre, 1959), there was no
evidence of an association between irregularity in
self-administration of the PH regimen and un-
favourable response.
Thus, further evidence has been obtained that the
problem of ensuring the self-administration of
medicine is not confined to a particular drug, and
some evidence has now been obtained that default
may carry therapeutic penalties. The planning of
mass campaigns against tuberculosis must pay
particular attention to this aspect, especially if a
chemotherapy of borderline effectiveness is to be used.
More than half the HI-2 and H patients who gave
no evidence of irregularity in the self-administration
of their medicine showed an unfavourable response
at 12 months, so that these two regimens were still
clearly unsatisfactory even when the drug was
apparently being taken regularly.
DOSAGE AND RHYTHM OF ADMINISTRATION
There was very little difference between the clinical
effectiveness of the HI-2 and H regimens, which is
the more remarkable since the HI-2 regimen con-
sisted of double the dosage of isoniazid given in the
H regimen. Therefore, to increase the total daily
dosage of isoniazid does not necessarily give greater
therapeutic effectiveness; this observation is contrary
to the suggestions of Kass et al. (1957) and Levy et
al. (1960). On the other hand, the HI-1 treatment,
in which the same daily dosage of isoniazid was given
as in the HI-2 regimen, but as one instead of two
doses, was the more effective of the two. Thus, in
the present study the rhythm of administration of the
isoniazid has proved more important than the total
daily dosage. There is indirect evidence also that the
rhythm of administration of PAS in drug combina-
tions may possibly influence the effectiveness of the
combination, for 10 g of PAS (sodium) given as two
doses of 5 g a day with isoniazid prevented the
emergence of isoniazid resistance (Great Britain,
Medical Research Council, 1955), but when given
in four divided doses of 2.5 g with streptomycin was
le s satisfactory in preventing streptomycin resistance
(Great Britain, Medical Research Council, 1952a).
On the other hand, 20 g daily given in four doses of
5 g a day with streptomycin was effective in prevent-
ing streptomycin resistance (Great Britain, Medical
Res arch Council, 1952a). It is possible that the
latter dosage was effective because the individual
doses of PAS were 5 g, and not because the total
aily dosage was 20 g.
Th  much greater effectiveness of the PH regimen
than either the H or the HI-2 regimen provides
information on the mechanism of action of the
combination. Evidence has been reported that, in
the combination isoniazid plus PAS, the action of
the PAS is only in part directly on the tubercle
bacilli, being in part due also to competition with
isoniazid for acetylation, so that the effective serum
isoni zid level is increased (Johnson & Corte, 1956;
Morse et al., 1956; Mandel et al., 1956; Grosset et
al., 1958). The findings of the present study suggest
that the direct role of PAS on tubercle bacilli is much
the more important of the two. The HI-2 regimen
consisted of twice as much isoniazid as the H
regimen, and yet proved no more effective. The PH
regim n contained only the same low dosage of
isoniazid as the H regimen, but proved very much
more effective.
PRlMARY BACTERIAL RESISTANCE TO THE DRUGS
The patients and their relatives were interrogated
about previous chemotherapy on several occasions,
and wherever possible other inquiries were made.
After excluding any patients who might possibly
have had previous chemotherapy, primary drug
resistance to isoniazid was found in 5.9% and to
streptomycin in 3.3 % of the patients. (For reasons
referred to in the present report and reported fully
elsewhere by Selkon et al. (1960) l, the prevalence of
primary PAS resistance has not been defined with
certainty.) The figures do not differ significantly
from those in the earlier study (Tuberculosis Chemo-
therapy Centre, 1959), in which the prevalence of
drug resistance to isoniazid in previously untreated
patients was 3.8 % and to streptomycin 2.3 %.
In the present study, as in East Africa (East
African/British Medical Research Council Isoniazid
1 See article on page 599 of this issue.
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Investigation,1960) clear evidence was obtained of
bacteriological disadvantage to the patients of
primary isoniazid-resistant organisms, when treated
with isoniazid alone. However, the present results,
unlike the East African findings, indicate that the
combination isoniazid plus PAS was also an un-
satisfactory treatment for such patients. Of the six
patients in the PH series with primary isoniazid
resistance, five had an unfavourable bacteriological
response, compared with eight of 86 with sensitive
organisms initially, a statistically highly significant
difference. It may be concluded that none of the
treatments studied was effective in primary isoniazid-
resistant infections.
FURTHER FINDINGS
In the course of the present study a great deal of
information has been obtained for the four regimens
concerning the emergence of isoniazid resistance, the
catalase activity of the strains isolated before and
during treatment, the susceptibility of the strains to
hydrogen peroxide, and the virulence of the strains
before and during treatment, as well as on the serum
is n azid levels of the patients. This material is in
the process of analysis and will be the subject of a
series of further publications. It is hoped that in the
ligh  of all these further data it will become possible
to un erstand more clearly the reasons for the  
differences in response between the four regimens.
XIV. SUMMARY
1. A total of 341 South Indian patients with acute
pulmonary tuberculosis was admitted to a com-
parison of treatment with four different oral chemo-
therapeutic regimens for a period of 12 months at
home, the patients being allocated at random to
the four treatment series.
2. The intake of patients began in October 1957 and
ended in December 1958.
3. The regimens (and the dosages appropriate to
patients weighing 100 lb. (45.4 kg)) were: (1) PH
-isoniazid 200 mg plus PAS (sodium) 10 g a day,
given together in the same cachet, in two equal
doses; (2) HI-1–isoniazid 400 mg a day in one
dose; (3) HI-2–isoniazid 400 mg a day in two equal
doses; (4) H–isoniazid 200 mg a day in two equal
doses. The dosage of each regimen was graded
according to the patient’s weight.
4. Patients on the PH and H regimens received a
mean daily dosage of isoniazid of 4.6 mg/kg body-
weight at the start of treatment; the HI-1 and HI-2
patients received an average of 8.7 mg/kg. The
mean daily dosage of PAS in the PH regimen was
0.23 g/kg.
5. Only one patient was lost from observation in the
12-month period ;even he was re-examined at
12 months.
6. The main analysis in this report concerns 315
of the 341 patients-namely, the 90 PH, 70 HI-1,
68 HI-2, and 87 H patients who (a) had organisms
sensitive to isoniazid on admission, (b) had had no
previous chemotherapy (a few had had up to two
weeks’ chemotherapy) and (c) followed the allocated
treatment regimen for 12 months unless it was
stopped owing to death or was changed because of
a deterioration or serious toxicity.
7. On admission to treatment the clinical and
bacteriological condition of the patients in all four
treatment series was similar, except that the patients
in the PH series had more extensive disease and a
smaller bacterial content of the sputum than those
in the other three series, and the patients in the
HI-2 series had strains of tubercle bacilli with a
lower virulence in the guinea-pig than those in the
other three series.
8. Over the 12 months, 90% of 82 PH, 90% of
60 HI-1, 69 % of 64 HI-2 and 69 % of 81 H patients
gained weight. All four series showed a progressive 
increase in the numbers of patients with a low 
ESR. Most of the patients showed at least moderate
radiographic improvement-namely, 85 % of the
PH, 78 % of the HI-1, 71% of the HI-2 and 62 % of
the H series. In patients with cavitation of moderate
extent on admission (for which the numbers were
relatively large), the cavitation had disappeared by
12 months in 63% of 41 PH, 52% of 31 HI-1,
39% of 38 HI-2, and 38% of 45 H patients.
9. At 12 months the cultures from 90% of the
PH, 76 % of the HI-1, 59 % of the HI-2 and 51%
of the H patients were negative.Resistance to
isoniazid emerged rapidly in the three isoniazid-
alone series and more slowly in the PH series. From
six months onwards nearly all the positive cultures
in all four series were isoniazid-resistant.
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10. During the course of the year serious clinical
or radiographic deterioration necessitating a change
of chemotherapy occurred in 1% of the PH, 7 %
of the HI-1, 21% of the HI-2 and 17% of the
H series.
11. Using very stringent criteria to assess the
response to treatment, 8% of the PH, 27% of the
HI-1, 41 % of the HI-2 and 52 % of the H patients
were classified as having bacteriologically relapsed
or bacteriologically active disease at the end of
12 months (including those who had deteriorated
and so had their chemotherapy changed). In addi-
tion, one PH, one HI-2 and three H patients had
died of tuberculosis.
12. After statistical standardization for the pre-
treatment differences in virulence, the relatively
small differences in response between the HI-2 and
H series practically disappeared.
13. Peripheral neuritis attributed to the isoniazid
cccurred in one (1%) of the PH, 13 (19 %) of the
HI-1, six (9%) of the HI-2, and none of the H
patients. The clinical picture was mainly sensory,
and progression was slow in 18 of the 20 patients.
14. Primary infectionoccurred with isoniazid-
resistant organisms in 5.9 % of the patients and with
streptomycin-resistant organisms in 3.3 %. The
identification of patients with PAS-resistant strains
before treatment was difficult.
15. Five of the six PH patients with primary
isoniazid-resistant organisms had an unfavourable
response (defined as bacteriologically relapsed or
bacteriologically active disease at 12 months, in-
 cluding change of chemotherapy due to deteriora-
tion, or tuberculous death), compared with eight of
86 with isoniazid-sensitive organisms.O f  t h e
14 patients with primary isoniazid resistance in the
three isoniazid-alone regimens combined, 12 had an
unfavourable response to the prescribed treatment,
compared with 93 of 216 with sensitive organisms. Both
these differences are statistically highly significant.
16. The self-administration of the cachets and
tablets was checked by tests on the urine. There
were only minor differences between the four series
in the proportions of patients with negative results.
Ther  was, therefore, evidence that the large PAS-
containing cachets were as acceptable for self-
administration as the same number of smaller
isoniazid-containing tablets, and that isoniazid alone
was equally acceptable in one or in two doses a day.
More irregularity in self-administration was found
among female than among male patients.
17. In conclusion, this study has confirmed that
the combination isoniazid plus PAS, given for
12 months, is a satisfactory domiciliary treatment
for pulmonary tuberculosis in Madras City, even
though the group of patients under study had poor
accommodation, little rest, a poor diet, practically
no nursing and were not supervised in taking their
medicines. The two isoniazid-alone regimens given
as two doses a day were unsatisfactory in their
clinical effectiveness, whether the total daily dosage
ranged (for the majority of patients) from 3.9 to
5.5 mg/kg (H) or 7.8 to 9.6 mg/kg (HI-2), and
peripheral neuritis was a complication with the
larger dosage.In contrast, the isoniazid-alone
regimen consisting of a single daily dose of 7.8-
9.6 mg/kg (HI-1)was more satisfactory in its
clinical effectiveness, though peripheral neuritis was
again a disadvantage.Even if there had been no
peripheral neuritis with this large dose of isoniazid,
however, the regimen would still have been regarded
as less satisfactory than isoniazid plus PAS, on the
grounds of clinical effectiveness.
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